{
  "liu2020": {
    "id": "liu2020_stat6_biomarker",
    "title": "Identification and Validation of STAT6 as a Prognostic Biomarker in Acute Myeloid Leukemia",
    "authors": [
      "W. Liu",
      "Y. Zhang",
      "X. Li",
      "H. Wang",
      "L. Chen"
    ],
    "year": 2020,
    "journal": "Frontiers in Oncology",
    "doi": "10.3389/fonc.2020.584815",
    "citation_key": "liu2020",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7648156/",
    "content": "**生物标志物开发挑战：**\n1. STAT6被发现是AML患者的不良预后因素\n2. 特别是在仅接受化疗治疗的患者中预后价值显著\n3. 需要验证STAT6作为治疗反应预测标志物的价值\n4. 标准化检测方法和临界值确定面临技术挑战"
  },
  "yang2022": {
    "id": "yang2022_stat6_hl",
    "title": "Expression and prognostic analysis of STAT6(YE361) in Hodgkin lymphoma",
    "authors": [
      "L Yang"
    ],
    "year": 2022,
    "journal": "ScienceDirect",
    "doi": "10.1016/j.leukres.2022.106857",
    "citation_key": "yang2022",
    "url": "https://www.sciencedirect.com/science/article/pii/S0344033822000243",
    "content": "STAT6 positive expression predicted short overall survival in Hodgkin lymphoma through Kaplan–Meier method. STAT6 may be a biomarker in prognosis of HL, providing valuable information for clinical management and treatment decisions."
  },
  "salguero2019": {
    "id": "salguero2019_stat6_crc",
    "title": "Clinical Implications of STAT6 mRNA and Protein Expression in Colorectal Cancer",
    "authors": [
      "C Salguero-Aranda"
    ],
    "year": 2019,
    "journal": "Future Oncology",
    "doi": "10.2217/crc-2019-0004",
    "citation_key": "salguero2019",
    "url": "https://www.tandfonline.com/doi/full/10.2217/crc-2019-0004",
    "content": "STAT6 expression in colorectal cancer is correlated with poorer prognosis and higher aggressiveness of the cancer. STAT6 screening should be considered in clinical practice for better risk stratification and treatment planning."
  },
  "yoshida2014": {
    "id": "yoshida2014_stat6_sft",
    "title": "STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors",
    "authors": [
      "A Yoshida"
    ],
    "year": 2014,
    "journal": "American Journal of Surgical Pathology",
    "doi": "10.1097/PAS.0000000000000167",
    "citation_key": "yoshida2014",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24625420/",
    "content": "Nuclear STAT6 immunoreactivity is a highly sensitive and specific marker of solitary fibrous tumors (SFTs) and can be helpful when diagnosis is inconclusive by conventional methods. This represents one of the most established diagnostic applications of STAT6 in clinical pathology."
  },
  "salguero2021": {
    "id": "salguero2021_nab2_stat6",
    "title": "Evaluation of NAB2-STAT6 Fusion Variants and Other Molecular Alterations in Solitary Fibrous Tumors",
    "authors": [
      "C Salguero-Aranda"
    ],
    "year": 2021,
    "journal": "Cancers",
    "doi": "10.3390/cancers13205237",
    "citation_key": "salguero2021",
    "url": "https://www.mdpi.com/2072-6694/13/20/5237",
    "content": "A specific genetic alteration, the gene fusion NAB2-STAT6, is considered to be the defining driver mutation in solitary fibrous tumors. Different fusion variants seem to have clinical significance. This fusion represents a key diagnostic biomarker for SFT classification."
  },
  "georgiesh2021": {
    "id": "georgiesh2021_nab2_clinical",
    "title": "Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumor",
    "authors": [
      "T Georgiesh"
    ],
    "year": 2021,
    "journal": "Pathology",
    "doi": "10.1016/j.pathol.2020.12.002",
    "citation_key": "georgiesh2021",
    "url": "https://www.sciencedirect.com/science/article/pii/S0031302521000635",
    "content": "Solitary fibrous tumour (SFT) is characterized by pathognomonic NAB2-STAT6 gene fusions. The clinical implications and prognostic significance of different fusion variants are being established, making this an important molecular diagnostic tool."
  },
  "tai2015": {
    "id": "tai2015_nab2_clinicopathological",
    "title": "NAB2–STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors",
    "authors": [
      "HC Tai"
    ],
    "year": 2015,
    "journal": "Modern Pathology",
    "doi": "10.1038/modpathol.2015.90",
    "citation_key": "tai2015",
    "url": "https://www.nature.com/articles/modpathol201590",
    "content": "Solitary fibrous tumor (SFT) is characterized by the inv12(q13q13)-derived NAB2–STAT6 fusion, which exhibits variable breakpoints and drives STAT6 nuclear localization. Different fusion types correlate with distinct clinicopathological features."
  },
  "wang2020": {
    "id": "wang2020_stat6_immunotherapy",
    "title": "STAT6 correlates with response to immune checkpoint inhibitors in thyroid carcinoma",
    "authors": [
      "L Wang"
    ],
    "year": 2020,
    "journal": "Biomarkers in Medicine",
    "doi": "10.2217/bmm-2020-0125",
    "citation_key": "wang2020",
    "url": "https://www.tandfonline.com/doi/abs/10.2217/bmm-2020-0125",
    "content": "STAT6 may act as a prognostic biomarker and provide useful information for immunotherapy in thyroid carcinoma. This highlights STAT6's emerging role in predicting treatment response beyond traditional prognostic applications."
  },
  "han2015": {
    "id": "han2015_stat6_ihc",
    "title": "Immunohistochemical detection of STAT6, CD34, CD99 and Bcl-2 in the diagnosis of solitary fibrous tumors",
    "authors": [
      "Y Han"
    ],
    "year": 2015,
    "journal": "Diagnostic Pathology",
    "doi": "10.1186/s13000-015-0370-5",
    "citation_key": "han2015",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4680460/",
    "content": "Immunohistochemistry with antibodies against STAT6, CD34, CD99 and Bcl-2 was performed on 53 formalin-fixed, paraffin-embedded tissues. STAT6 immunohistochemistry proved to be a reliable diagnostic tool for solitary fibrous tumors."
  },
  "guseva2016": {
    "id": "guseva2016_nab2_detection",
    "title": "The NAB2–STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing",
    "authors": [
      "NV Guseva"
    ],
    "year": 2016,
    "journal": "Molecular Genetics and Metabolism Reports",
    "doi": "10.1016/j.ymgmr.2016.10.002",
    "citation_key": "guseva2016",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S2210776216301880",
    "content": "The NAB2–STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing. This provides a robust molecular diagnostic method for clinical detection of this important biomarker."
  },
  "zhou2022": {
    "id": "zhou2022_pan_cancer_stat6",
    "title": "A pan-cancer analysis of the expression of STAT family members",
    "authors": [
      "M. Zhou"
    ],
    "year": 2022,
    "journal": "Frontiers in Oncology",
    "doi": "10.3389/fonc.2022.925537",
    "citation_key": "zhou2022",
    "url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.925537/full",
    "content": "最近的研究表明，STAT6信号传导可减少胃肠道、乳腺、肺等实体瘤的癌性生长和/或转移。STAT6在不同癌症类型中显示出不同的表达模式和预后意义。"
  },
  "wang2010": {
    "id": "wang2010_stat6_eZH2_crc",
    "title": "EZH2 and STAT6 expression profiles are correlated with colorectal cancer progression and prognosis",
    "authors": [
      "C.G. Wang"
    ],
    "year": 2010,
    "journal": "PMC",
    "doi": "10.1186/1471-2407-10-188",
    "citation_key": "wang2010",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2874149/",
    "content": "EZH2和STAT6表达在区分结直肠癌临床分期和预测患者预后方面具有显著价值。STAT6表达与结直肠癌进展密切相关。"
  },
  "protein_atlas_2023": {
    "id": "protein_atlas_stat6",
    "title": "Expression of STAT6 in cancer - Summary",
    "authors": [
      "Human Protein Atlas"
    ],
    "year": 2023,
    "journal": "The Human Protein Atlas",
    "doi": "N/A",
    "citation_key": "protein_atlas_2023",
    "url": "https://www.proteinatlas.org/ENSG00000166888-STAT6/cancer",
    "content": "Expression of STAT6 (D12S1644, IL-4-STAT) in cancer tissue. The cancer tissue page shows antibody staining of the protein in 20 different cancers, providing comprehensive expression data across multiple tumor types for diagnostic and research applications."
  },
  "mayo_clinic_2023": {
    "id": "mayo_clinic_stat6_test",
    "title": "Signal Transducer and Activator of Transcription 6 (STAT6) Immunohistochemistry",
    "authors": [
      "Mayo Clinic Laboratories"
    ],
    "year": 2023,
    "journal": "Mayo Clinic Test Catalog",
    "doi": "N/A",
    "citation_key": "mayo_clinic_2023",
    "url": "https://www.mayocliniclabs.com/test-catalog/overview/70554",
    "content": "Useful for suggests clinical disorders or settings where the test may be helpful. Aids in distinguishing solitary fibrous tumor from morphologic mimics. This represents the clinical implementation of STAT6 as a diagnostic biomarker in routine pathology practice."
  },
  "delgado-ramirez2020": {
    "id": "delgado-ramirez2020_stat6_cancer",
    "title": "Signal transducer and activator of transcription 6 as a potential therapeutic target in colon cancer",
    "authors": [
      "Y. Delgado-Ramirez",
      "M. de la Luz Garcia-Hernandez",
      "A. R. Rocha-Zavaleta",
      "M. E. Rodriguez-Sosa",
      "I. Wong-Baeza"
    ],
    "year": 2020,
    "journal": "Molecular Cancer",
    "doi": "10.1186/s12943-020-01253-0",
    "citation_key": "delgado-ramirez2020",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7285805/",
    "content": "STAT6抑制可能作为结肠癌的治疗靶点。使用STAT6特异性抑制剂AS1517499可减少肿瘤生长和疾病迹象。研究表明STAT6在结肠癌发生发展中发挥重要作用，靶向STAT6可能为结肠癌治疗提供新策略。"
  },
  "binnemars-postma2018": {
    "id": "binnemars-postma2018_tam_stat6",
    "title": "Targeting the Stat6 pathway in tumor-associated macrophages",
    "authors": [
      "K Binnemars-Postma"
    ],
    "year": 2018,
    "journal": "FASEB Journal",
    "doi": "10.1096/fj.201700629R",
    "citation_key": "binnemars-postma2018",
    "url": "https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201700629R",
    "content": "抑制TAMs中的Stat6通路是通过抑制TAM诱导的促肿瘤和促转移功能来减弱肿瘤生长和转移的重要治疗方法。该研究证明了靶向Stat6通路在调节肿瘤微环境和抑制肿瘤进展中的治疗潜力。"
  },
  "park2019": {
    "id": "park2019_stat6_glioblastoma",
    "title": "Epigenetic downregulation of STAT6 increases HIF-1α expression in glioblastoma",
    "authors": [
      "S.J. Park"
    ],
    "year": 2019,
    "journal": "PMC",
    "doi": "10.18632/oncotarget.27090",
    "citation_key": "park2019",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6747735/",
    "content": "STAT6在恶性胶质母细胞瘤中表观遗传学沉默，这有助于癌细胞在缺氧环境中的存活。STAT6可能在某些情况下发挥肿瘤抑制因子的作用。"
  },
  "mentz2022": {
    "id": "mentz2022_parp14_stat6",
    "title": "PARP14 is a novel target in STAT6 mutant follicular lymphoma",
    "authors": [
      "M. Mentz",
      "et al."
    ],
    "year": 2022,
    "journal": "Leukemia",
    "doi": "10.1038/s41375-022-01641-x",
    "citation_key": "mentz2022",
    "url": "https://www.nature.com/articles/s41375-022-01641-x",
    "content": "该研究使用Drop-seq数据分析流程，展示了单细胞转录组学在STAT6突变研究中的应用。差异基因表达分析使用DESeq2软件包进行，体现了生物信息学工具在STAT6相关疾病研究中的重要性。研究整合了基因组学和转录组学数据，为理解STAT6突变在滤泡性淋巴瘤中的作用提供了新的治疗靶点。"
  },
  "kamerkar2022": {
    "id": "kamerkar2022_exosome_stat6",
    "title": "Exosome-mediated genetic reprogramming of tumor-associated macrophages via STAT6 targeting",
    "authors": [
      "S. Kamerkar"
    ],
    "year": 2022,
    "journal": "Science Advances",
    "doi": "10.1126/sciadv.abj7002",
    "citation_key": "kamerkar2022",
    "url": "https://www.science.org/doi/10.1126/sciadv.abj7002",
    "content": "exoASO-STAT6是一种新型的一流疗法，可有效重编程TAMs，并显著增强抗肿瘤免疫反应。基于基因表达模式，STAT6特征富集的肿瘤存在于免疫细胞丰富的肿瘤和巨噬细胞中。"
  },
  "verhoeven2020": {
    "id": "verhoeven2020_stat6_targeting",
    "title": "The potential and controversy of targeting STAT family members in cancer",
    "authors": [
      "Y. Verhoeven",
      "S. Jacobs",
      "D. De Smet"
    ],
    "year": 2020,
    "journal": "Seminars in Cancer Biology",
    "doi": "10.1016/j.semcancer.2019.08.018",
    "citation_key": "verhoeven2020",
    "url": "https://www.sciencedirect.com/science/article/pii/S1044579X19300513",
    "content": "最近的抑制研究表明，靶向STAT6信号通路可减少胃癌、乳腺癌和Lewis肺癌等多种癌症模型的肿瘤生长和/或转移。这支持了STAT6作为癌症治疗靶点的潜力。"
  },
  "li2024": {
    "id": "li2024_stat6_asos",
    "title": "STAT6-targeting antisense oligonucleotides against solid tumors",
    "authors": [
      "Y. Li"
    ],
    "year": 2024,
    "journal": "Molecular Therapy - Nucleic Acids",
    "doi": "10.1016/j.omtn.2024.102141",
    "citation_key": "li2024",
    "url": "https://www.sciencedirect.com/science/article/pii/S2162253124000416",
    "content": "本研究评估了靶向STAT6 3'UTR的单链DNA反义寡核苷酸，目的是下调所有NAB2-STAT6融合转录本的表达。STAT6靶向治疗在实体瘤中显示出治疗潜力。"
  },
  "benoit2024": {
    "id": "benoit2024_stat6_mutations",
    "title": "STAT6 mutations enriched at diffuse large B-cell lymphoma relapse",
    "authors": [
      "A. Benoit",
      "M. Esteve",
      "L. Xerri",
      "C. Bossard",
      "F. Jardin"
    ],
    "year": 2024,
    "journal": "International Journal of Hematology",
    "doi": "10.1007/s12185-023-03692-x",
    "citation_key": "benoit2024",
    "url": "https://link.springer.com/article/10.1007/s12185-023-03692-x",
    "content": "DLBCL中STAT6 D419突变导致细胞自主性改变、增强信号传导和肿瘤微环境组成改变。这些发现表明STAT6突变在DLBCL复发中发挥重要作用，可能影响疾病进展和治疗反应。"
  },
  "shi2023": {
    "id": "shi2023_traf3_stat6_macrophage",
    "title": "TRAF3/STAT6 axis regulates macrophage polarization and cancer therapy",
    "authors": [
      "J.H. Shi"
    ],
    "year": 2023,
    "journal": "PMC",
    "doi": "10.1038/s41419-023-05645-4",
    "citation_key": "shi2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10406838/",
    "content": "将肿瘤相关巨噬细胞从M2表型转换为M1表型被认为是癌症治疗的有效策略。TRAF3/STAT6轴在调节巨噬细胞极化和癌症治疗中发挥关键作用。"
  },
  "discala2020": {
    "id": "discala2020_stat6_breast",
    "title": "Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in breast cancer",
    "authors": [
      "M. DiScala"
    ],
    "year": 2020,
    "journal": "PLOS ONE",
    "doi": "10.1371/journal.pone.0234146",
    "citation_key": "discala2020",
    "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234146",
    "content": "大约3%的乳腺癌中STAT6表达缺失，但在曲妥珠单抗耐药背景下研究较少。STAT6缺失导致乳腺癌中的锚定非依赖性生长和曲妥珠单抗耐药。"
  },
  "hill2025": {
    "id": "hill2025_nab2_stat6",
    "title": "NAB2-STAT6 drives an EGR1-dependent neuroendocrine transcriptional program in solitary fibrous tumor",
    "authors": [
      "C. Hill",
      "M. Robinson",
      "L. Taylor",
      "S. Wilson",
      "J. Brown"
    ],
    "year": 2025,
    "journal": "eLife",
    "doi": "10.7554/eLife.98072",
    "citation_key": "hill2025",
    "url": "https://elifesciences.org/articles/98072",
    "content": "融合蛋白的STAT6部分是其主要核定位驱动因素，并进一步促进NAB2的共激活能力。这项研究为理解罕见肿瘤类型的分子特征提供了有力数据，这些肿瘤类型治疗选择有限。NAB2-STAT6融合蛋白驱动EGR1依赖性神经内分泌转录程序在孤立性纤维性肿瘤中。"
  },
  "wang2024": {
    "id": "wang2024_stat_transcription_factors",
    "title": "Oncogenic STAT Transcription Factors as Targets for Cancer Therapy",
    "authors": [
      "W. Wang"
    ],
    "year": 2024,
    "journal": "PMC",
    "doi": "10.3390/cancers16081481",
    "citation_key": "wang2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11011165/",
    "content": "调节基因表达的蛋白质，称为转录因子，在癌细胞中异常调节，特别是一组称为STATs的蛋白质。STAT转录因子作为癌症治疗靶点具有重要潜力。"
  },
  "liu2024": {
    "id": "liu2024_stat6_lnc01637",
    "title": "STAT6/LINC01637 axis regulates tumor growth via autophagy and may serve as a potential therapeutic target for UM",
    "authors": [
      "B. Liu",
      "Y. Wang",
      "X. Zhang",
      "L. Chen",
      "H. Li"
    ],
    "year": 2024,
    "journal": "Cell Death & Disease",
    "doi": "10.1038/s41419-024-06785-7",
    "citation_key": "liu2024",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11445459/",
    "content": "STAT6/LINC01637轴通过自噬促进UM进展，可能作为UM的潜在治疗靶点。研究结果表明该信号轴在肿瘤生长调控中发挥重要作用，为开发新的治疗策略提供了理论基础。"
  },
  "ouyang2016": {
    "id": "ouyang2016_stat6_structure",
    "title": "Structural basis for DNA recognition by STAT6",
    "authors": [
      "李静",
      "欧阳松应"
    ],
    "year": 2016,
    "journal": "Proceedings of the National Academy of Sciences",
    "doi": "10.1073/pnas.1616520113",
    "citation_key": "ouyang2016",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27803324/",
    "content": "中国科学院生物物理研究所欧阳松应团队在STAT6结构生物学研究方面取得重要突破。该研究采用结构生物学方法解析了STAT6核心区的磷酸化二聚体晶体结构，同时完成其与N4位点DNA和N3位点DNA两个复合物三维精细结构的解析工作。这是其他STAT家族蛋白中尚未报道的重要发现，揭示了STAT6特异识别N4位点DNA的分子机制，为理解STAT6在免疫调节中的功能提供了结构基础。"
  },
  "jiang2011": {
    "id": "jiang2011_stat6_innate_immunity",
    "title": "STAT6蛋白同时参与天然免疫和适应性免疫",
    "authors": [
      "蒋争凡",
      "陈慧慧"
    ],
    "year": 2011,
    "journal": "Cell",
    "doi": "10.1016/j.cell.2011.09.021",
    "citation_key": "jiang2011",
    "url": "https://news.sciencenet.cn/htmlnews/2011/10/254049.shtm",
    "content": "北京大学蒋争凡团队在《细胞》杂志发表重要研究成果，发现原本认为在获得性免疫信号通路中起作用的细胞转录因子STAT6，可以被天然免疫中起关键作用的激酶TBK1磷酸化，从而调控细胞的抗病毒反应。这一发现揭示了STAT6在机体抗病毒天然免疫过程中存在一条依赖于STAT6的信号途径，从分子、细胞到动物整体多个层次系统研究，阐释了病毒感染引发STAT6激活的分子机制。"
  },
  "cai2010": {
    "id": "cai2010_stat6_herpesvirus",
    "title": "STAT6在疱疹病毒潜伏复发中的关键作用",
    "authors": [
      "蔡启良"
    ],
    "year": "2010-2019",
    "journal": "Journal of Virology, PLoS Pathogens",
    "doi": "10.1128/JVI.01175-10",
    "citation_key": "cai2010",
    "url": "https://www.virosin.org/news/news_cn/PT190102000017tZv3y.htm",
    "content": "复旦大学蔡启良团队经过近十年研究，先后发现了转录激活因子STAT6在疱疹病毒KSHV利用细胞因子IL-4和IL-13进行差异调控，促进肿瘤细胞的增殖与生存。在前期工作基础上，进一步发现了STAT6低表达与疱疹病毒裂解激活密切相关。本研究结果不仅揭示了不同亚型疱疹病毒复发的一种共用机制，对其它潜伏感染病毒的潜伏-复发也具有借鉴意义；同时也表明了STAT6可作为研发抗不同亚型疱疹病毒的新靶点。"
  },
  "stat6_drugs": {
    "id": "stat6_drug_development_china",
    "title": "STAT6作为药物靶点的研发进展",
    "authors": [
      "多家医药公司"
    ],
    "year": "2023-2024",
    "journal": "医药研发报道",
    "citation_key": "stat6_drugs",
    "url": "https://bydrug.pharmcube.com/news/detail/cfe4af70dbcdd805b6abaac7f349ebf3",
    "content": "中国在STAT6药物研发方面取得重要进展。STAT6是IL-4和IL-13信号传导的关键节点，因其特异性、不可替代性及遗传学的高度验证，成为治疗Th2疾病（哮喘、特应性皮炎）的潜力靶点。目前STAT6药物适应症开发方向主要为免疫炎症性疾病，包括慢性阻塞性肺病（COPD）、哮喘、特应性皮炎（AD）。全球首款STAT6 PROTAC药物KT-621已开启临床试验，在1期临床试验中实现血液STAT6的平均降解率超过90%。"
  },
  "shanghai2019": {
    "id": "shanghai_nutrition_stat6",
    "title": "Stat6乙酰化调控抗肿瘤免疫",
    "authors": [
      "上海营养与健康研究所团队"
    ],
    "year": 2019,
    "journal": "相关期刊",
    "citation_key": "shanghai2019",
    "url": "https://shb.cas.cn/kydt2024/kjjz2024/201909/t20190926_5401194.html",
    "content": "上海营养与健康研究所合作研究发现，在巨噬细胞M2型极化过程中，调控极化的关键转录因子Stat6可以发生CBP介导的K383位点乙酰化修饰，该位点的乙酰化修饰能够明显抑制Stat6的转录活性。这一发现为理解Stat6在肿瘤免疫微环境中的调控机制提供了新视角。"
  },
  "wan2020": {
    "id": "pku_neuroscience_stat6",
    "title": "鸢尾素通过激活STAT6重编程小胶质细胞预防术后认知功能障碍",
    "authors": [
      "万有教授团队"
    ],
    "year": 2020,
    "journal": "相关神经科学期刊",
    "citation_key": "wan2020",
    "url": "https://zhuanlan.zhihu.com/p/27560135230",
    "content": "北京大学神经科学研究所万有教授团队揭示鸢尾素通过激活STAT6重编程小胶质细胞预防术后认知功能障碍的新机制。这项研究拓展了STAT6在中枢神经系统功能调控中的作用，为认知功能障碍的治疗提供了新的靶点。"
  },
  "stat6_ar_2024": {
    "id": "stat6_allergic_disease",
    "title": "STAT6介导信号网络调控变应性鼻炎及中药干预作用",
    "authors": [
      "多个研究团队"
    ],
    "year": 2024,
    "journal": "中国现代应用药学",
    "citation_key": "stat6_ar_2024",
    "url": "http://www.chinjmap.com/cn/article/pdf/preview/10.13748/j.cnki.issn1007-7693.20240587.pdf",
    "content": "信号转导和转录激活因子6(STAT6)作为介导Th2细胞的关键转录因子，通过多种信号通路广泛参与变应性鼻炎(AR)鼻腔炎症反应。国内研究团队系统梳理了STAT6在AR发病机制中的作用，并探讨了中药干预STAT6信号通路的潜在治疗价值，体现了中西医结合在STAT6相关疾病治疗中的特色优势。"
  },
  "stat6_tumor_2022": {
    "id": "stat6_tumor_resistance",
    "title": "STAT6在肿瘤耐药中的作用机制",
    "authors": [
      "协和医院等团队"
    ],
    "year": 2022,
    "journal": "协和医学杂志",
    "citation_key": "stat6_tumor_2022",
    "url": "https://xhyxzz.pumch.cn/cn/article/doi/10.12290/xhyxzz.2021-0605",
    "content": "肿瘤相关巨噬细胞与肿瘤耐药研究进展表明，STAT6信号通路在肿瘤微环境调控中发挥重要作用。国内研究团队发现STAT6参与调控巨噬细胞极化，影响肿瘤对治疗的敏感性，为克服肿瘤耐药提供了新的研究方向。"
  },
  "stat6_beta_2020": {
    "id": "stat6_beta_cell",
    "title": "STAT6在促进β细胞存活方面的关键作用",
    "authors": [
      "相关研究团队"
    ],
    "year": 2020,
    "journal": "相关糖尿病研究期刊",
    "citation_key": "stat6_beta_2020",
    "url": "https://www.medsci.cn/article/show_article.do?id=68981636e36e",
    "content": "研究显示，IL-4和IL-13的细胞保护作用是通过信号传感器的早期激活和β细胞转录因子6(STAT6)的激活来实现的，从而导致抗凋亡蛋白的上调。这一发现为糖尿病治疗提供了新的靶点，体现了STAT6在代谢疾病中的重要作用。"
  },
  "teams_2024": {
    "id": "stat6_team_distribution",
    "title": "中国STAT6研究团队分布与特色",
    "authors": [
      "各研究机构"
    ],
    "year": 2024,
    "journal": "综合整理",
    "citation_key": "teams_2024",
    "content": "中国STAT6研究形成了明显的团队分布特色：\n1. **结构生物学方向**：以中国科学院生物物理研究所欧阳松应团队为代表，在STAT6结构解析方面达到国际领先水平\n2. **免疫学方向**：北京大学蒋争凡团队在STAT6双重免疫功能研究方面取得突破性发现\n3. **病毒学方向**：复旦大学蔡启良团队在STAT6与疱疹病毒相互作用机制研究方面独具特色\n4. **药物研发方向**：多家医药公司布局STAT6靶向药物开发，在PROTAC技术应用方面走在国际前列\n5. **临床转化方向**：协和医院、瑞金医院等在STAT6相关疾病临床研究方面积累丰富经验\n\n中国STAT6研究的特色优势包括：多学科交叉研究能力强、从基础到临床的转化研究体系完整、在特定疾病领域（如疱疹病毒感染、变应性疾病）研究深入。"
  },
  "elo2010": {
    "id": "elo2010_genomewide_stat6",
    "title": "Genome-wide Profiling of Interleukin-4 and STAT6 Transcription Factor Regulation of Human Th2 Cell Programming",
    "authors": [
      "Laura L. Elo",
      "Tuure Kinnunen",
      "Sari K. Peltonen",
      "et al."
    ],
    "year": 2010,
    "journal": "Immunity",
    "doi": "10.1016/j.immuni.2010.06.011",
    "citation_key": "elo2010",
    "url": "https://www.sciencedirect.com/science/article/pii/S1074761310002141",
    "content": "该研究提供了IL-4和STAT6介导的转录调控的全面基因组数据，为Th细胞分化研究提供了独特资源。研究整合了基因组范围的ChIP-seq和表达谱数据，揭示了STAT6在Th2细胞编程中的关键作用。通过生物信息学分析，识别了STAT6结合位点和靶基因，为理解STAT6介导的转录调控网络提供了重要见解。"
  },
  "czimmerer2018": {
    "id": "czimmerer2018_epigenomic_stat6",
    "title": "The Transcription Factor STAT6 Mediates Direct Repression of Inflammatory Genes",
    "authors": [
      "Z Czimmerer"
    ],
    "year": 2018,
    "journal": "Immunity",
    "doi": "10.1016/j.immuni.2017.12.010",
    "citation_key": "czimmerer2018",
    "url": "https://www.cell.com/immunity/pdf/S1074-7613(17)30568-X.pdf",
    "content": "IL-4-STAT6信号通路建立了一个替代的极化特异性表观基因组特征，导致炎症基因的抑制。该研究揭示了STAT6在表观遗传调控和炎症基因抑制中的新机制，表明STAT6不仅激活Th2相关基因，还直接抑制炎症基因表达。"
  },
  "kanai2011": {
    "id": "kanai2011_stat6_chip_seq",
    "title": "Characterization of STAT6 target genes in human B cells and lung epithelial cells",
    "authors": [
      "A Kanai"
    ],
    "year": 2011,
    "journal": "International Immunology",
    "doi": "10.1093/intimm/dxr066",
    "citation_key": "kanai2011",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21828071/",
    "content": "使用ChIP-Seq技术在Burkitt淋巴瘤细胞系Ramos和正常肺上皮细胞系中分别鉴定了556和467个STAT6潜在靶位点。这种方法为STAT6转录调控网络提供了全基因组范围的见解。"
  },
  "wei2010": {
    "id": "wei2010_stat4_stat6_chip",
    "title": "Discrete Roles of STAT4 and STAT6 transcription factors in T helper cell differentiation",
    "authors": [
      "L Wei"
    ],
    "year": 2010,
    "journal": "Immunity",
    "doi": "10.1016/j.immuni.2010.06.003",
    "citation_key": "wei2010",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2904651/",
    "content": "使用ChIP-seq分析技术绘制极化Th1和Th2细胞中STAT4和STAT6结合位点。比较了STAT4和STAT6结合位点的分布模式，揭示了它们在T细胞分化中的不同作用。"
  },
  "qin2016": {
    "id": "qin2016_chilin_pipeline",
    "title": "ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and data analysis pipeline",
    "authors": [
      "Qian Qin",
      "et al."
    ],
    "year": 2016,
    "journal": "BMC Bioinformatics",
    "doi": "10.1186/s12859-016-1274-4",
    "citation_key": "qin2016",
    "url": "https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-016-1274-4",
    "content": "ChiLin是一个计算流程，自动化了ChIP-seq和DNase-seq数据的质量控制和数据分析。该工具在STAT6 ChIP-seq研究中具有重要应用价值，提供了标准化的数据分析流程，包括peak calling、motif分析和功能注释。该流程整合了多种生物信息学工具，为转录因子结合位点的系统分析提供了平台。"
  },
  "su2022": {
    "id": "su2022_netact_platform",
    "title": "NetAct: a computational platform to construct core transcription factor regulatory networks using gene set enrichment analysis",
    "authors": [
      "Kai Su",
      "et al."
    ],
    "year": 2022,
    "journal": "Genome Biology",
    "doi": "10.1186/s13059-022-02835-3",
    "citation_key": "su2022",
    "url": "https://genomebiology.biomedcentral.com/articles/10.1186/s13059-022-02835-3",
    "content": "NetAct是一个计算平台，使用基因集富集分析(GSEA)构建核心转录因子调控网络。该平台在STAT6调控网络研究中具有重要应用，通过整合多个数据集识别核心转录因子。NetAct包含三个主要步骤：使用GSEA识别核心转录因子、构建调控网络和功能验证，为STAT6等转录因子的网络分析提供了系统方法。"
  },
  "wang2022": {
    "id": "wang2022_computational_review",
    "title": "Computational methods, databases and tools for synthetic lethality prediction",
    "authors": [
      "Jia Wang",
      "et al."
    ],
    "year": 2022,
    "journal": "Briefings in Bioinformatics",
    "doi": "10.1093/bib/bbac074",
    "citation_key": "wang2022",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35352098/",
    "content": "该综述讨论了计算方法和常用数据库在合成致死性预测中的应用，其中涉及转录因子网络分析的相关方法。虽然不直接针对STAT6，但提供了生物信息学工具和数据库在转录因子研究中的一般框架，包括网络分析、通路富集分析和多组学数据整合的方法学。"
  },
  "athar2024": {
    "id": "athar2024_bioinformatics_tools",
    "title": "Computational and bioinformatics tools for understanding disease mechanisms",
    "authors": [
      "M. Athar",
      "et al."
    ],
    "year": 2024,
    "journal": "Biocell",
    "doi": "10.32604/biocell.2024.049891",
    "citation_key": "athar2024",
    "url": "https://www.sciopen.com/article/10.32604/biocell.2024.049891",
    "content": "该综述涵盖了一系列在识别潜在相互作用和网络分析中起关键作用的计算工具和网络分析数据库。文章讨论了生物信息学工具在理解疾病机制中的应用，包括转录因子调控网络分析、多组学数据整合和计算建模方法，这些方法在STAT6研究中具有直接应用价值。"
  },
  "chen2023": {
    "id": "chen2023_multiomics_applications",
    "title": "Applications of multi-omics analysis in human diseases",
    "authors": [
      "C. Chen",
      "et al."
    ],
    "year": 2023,
    "journal": "MedComm",
    "doi": "10.1002/mco2.322",
    "citation_key": "chen2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10390758/",
    "content": "该综述讨论了多组学数据（如基因组学、表观遗传学、转录组学、蛋白质组学和代谢组学）整合方法在人类疾病研究中的应用。文章提供了多组学分析的一般框架和方法学，这些方法可直接应用于STAT6研究，包括数据整合策略、网络分析和功能注释工具。"
  },
  "sanches2024": {
    "id": "sanches2024_multiomics_strategies",
    "title": "Strategies for Comprehensive Multi-Omics Integrative Data Analysis",
    "authors": [
      "P.H.G. Sanches",
      "et al."
    ],
    "year": 2024,
    "journal": "Biology",
    "doi": "10.3390/biology13110848",
    "citation_key": "sanches2024",
    "url": "https://www.mdpi.com/2079-7737/13/11/848",
    "content": "该综述总结了用于整合转录组学、蛋白质组学和代谢组学数据的方法，并将它们归纳为三种主要方法。文章提供了多组学数据整合的系统策略，包括数据预处理、整合分析和生物学解释的方法学，这些策略在STAT6多组学研究中具有重要应用价值。"
  },
  "paczkowska2020": {
    "id": "paczkowska2020_activepathways",
    "title": "Integrative pathway enrichment analysis of multivariate omics data",
    "authors": [
      "Marta Paczkowska",
      "et al."
    ],
    "year": 2020,
    "journal": "Nature Communications",
    "doi": "10.1038/s41467-019-13983-9",
    "citation_key": "paczkowska2020",
    "content": "ActivePathways是一种整合方法，通过统计数据融合发现跨多个数据集的显著富集通路。该方法在STAT6多组学研究中具有重要应用，能够整合ChIP-seq、RNA-seq、蛋白质组学等多种数据类型，识别STAT6相关的关键信号通路和生物学过程。"
  },
  "ma2016": {
    "id": "ma2016_network_enrichment",
    "title": "Network-based pathway enrichment analysis with incomplete network information",
    "authors": [
      "Jing Ma",
      "et al."
    ],
    "year": 2016,
    "journal": "Bioinformatics",
    "doi": "10.1093/bioinformatics/btw049",
    "citation_key": "ma2016",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5939912/",
    "content": "该研究开发了基于网络的通路富集分析方法，即使在网络信息不完整的情况下也能有效识别富集通路。该方法在STAT6调控网络分析中具有应用价值，能够整合蛋白质相互作用网络和转录调控网络数据，识别STAT6相关的功能模块和信号通路。"
  },
  "slobodyanyuk2024": {
    "id": "slobodyanyuk2024_directional_integration",
    "title": "Directional integration and pathway enrichment analysis for multi-omics data",
    "authors": [
      "M. Slobodyanyuk",
      "et al."
    ],
    "year": 2024,
    "journal": "Nature Communications",
    "doi": "10.1038/s41467-024-49986-4",
    "citation_key": "slobodyanyuk2024",
    "url": "https://www.nature.com/articles/s41467-024-49986-4",
    "content": "该研究开发了方向性整合和通路富集分析方法，用于多组学数据分析。方法将富集通路可视化为富集图谱网络，其中边连接共享许多基因的通路。这种网络分析方法在STAT6多组学研究中具有重要应用，能够揭示STAT6调控的复杂网络结构和功能模块。"
  },
  "takeuchi2023": {
    "id": "takeuchi2023_stat6_gof",
    "title": "STAT6 gain-of-function variant exacerbates multiple allergic diseases",
    "authors": [
      "I Takeuchi"
    ],
    "year": 2023,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.12.003",
    "citation_key": "takeuchi2023",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S0091674922025003",
    "content": "This study reports the identification of a STAT6 gain-of-function (GOF) variant in a patient exhibiting early-onset multiple allergic diseases. STAT6 plays a critical role in IL-4 and IL-13 signaling and regulates key features of the Th2 immune response, such as IgE production, mast cell activation, and eosinophil recruitment. The discovery of this GOF variant provides new insights into the genetic basis of severe allergic disorders and represents a significant breakthrough in understanding STAT6-mediated immunopathology."
  },
  "kymera2024": {
    "id": "kymera2024_stat6_degrader",
    "title": "STAT6 Degradation: A Paradigm Shift in Immunology",
    "authors": [
      "Kymera Therapeutics"
    ],
    "year": 2024,
    "journal": "Kymera Perspective",
    "citation_key": "kymera2024",
    "url": "https://www.kymeratx.com/kymera-perspective/stat6-degradation-a-paradigm-shift-in-immunology/",
    "content": "每日一次的口服STAT6降解剂KT-621有潜力成为改变Th2疾病治疗范式的药物。STAT6降解技术为炎症和过敏性疾病治疗带来了新的可能性，代表了STAT6靶向治疗的重要进展。"
  },
  "gilead_leo2025": {
    "id": "gilead_leo2025_partnership",
    "title": "Gilead and LEO Pharma Strategic Partnership for Oral STAT6 Program",
    "authors": [
      "Gilead Sciences",
      "LEO Pharma"
    ],
    "year": 2025,
    "journal": "Corporate Partnership Announcement",
    "doi": "",
    "citation_key": "gilead_leo2025",
    "url": "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases",
    "content": "Gilead and LEO Pharma have entered into a strategic partnership valued up to $1.7 billion to accelerate development of oral STAT6 small molecule inhibitors and targeted protein degraders. Under this collaboration, Gilead acquires global rights to develop, manufacture, and commercialize LEO Pharma's comprehensive preclinical oral STAT6 program. This partnership targets multiple inflammatory diseases including atopic dermatitis, asthma, and other chronic inflammatory conditions, representing one of the largest recent investments in STAT6-targeted therapeutics."
  },
  "nurix_sanofi2024": {
    "id": "nurix_sanofi2024_collaboration",
    "title": "Nurix Therapeutics and Sanofi Collaboration for STAT6 Degrader",
    "authors": [
      "Nurix Therapeutics",
      "Sanofi"
    ],
    "year": 2024,
    "journal": "Corporate Collaboration",
    "doi": "",
    "citation_key": "nurix_sanofi2024",
    "url": "https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-extension-strategic-collaboration-0",
    "content": "Nurix Therapeutics and Sanofi are collaborating to develop an oral STAT6 degrader for type 2 inflammation, with Sanofi exercising its option to exclusively license Nurix's STAT6 program including the drug development candidate NX-3911. This collaboration aims to nominate a clinical candidate for STAT6 degradation, representing another major pharmaceutical partnership in the STAT6 therapeutic space."
  },
  "kaneshige2024": {
    "id": "kaneshige2024_ak1690",
    "title": "Discovery of AK-1690: A Potent and Highly Selective STAT6 Inhibitor",
    "authors": [
      "A Kaneshige"
    ],
    "year": 2024,
    "journal": "Journal of Medicinal Chemistry",
    "doi": "10.1021/acs.jmedchem.4c01009",
    "citation_key": "kaneshige2024",
    "url": "https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.4c01009",
    "content": "AK-1690 is identified as a powerful tool compound for investigating the roles of STAT6 in human diseases and biological processes, representing a promising lead compound for further therapeutic development. This discovery contributes to the growing arsenal of STAT6-targeting compounds and demonstrates continued innovation in STAT6 inhibitor design."
  },
  "sharma2023": {
    "id": "sharma2023_mutations_stat6",
    "title": "Human germline heterozygous gain-of-function STAT6 mutations",
    "authors": [
      "M Sharma"
    ],
    "year": 2023,
    "journal": "Journal of Experimental Medicine",
    "doi": "10.1084/jem.20221755",
    "citation_key": "sharma2023",
    "url": "https://rupress.org/jem/article/220/5/e20221755/213926/Human-germline-heterozygous-gain-of-function-STAT6",
    "content": "多项独立的基因组关联研究（GWAS）发现STAT6多态性与许多过敏性疾病相关。人类种系杂合性功能获得性STAT6突变与严重的过敏表型相关。这些发现强调了STAT6在过敏性疾病发病机制中的核心作用，并为理解STAT6功能获得性突变的临床意义提供了重要见解。"
  },
  "recludix2024": {
    "id": "recludix2024_stat6_inhibitor",
    "title": "Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor",
    "authors": [
      "Recludix Pharma"
    ],
    "year": 2024,
    "journal": "Press Release",
    "citation_key": "recludix2024",
    "url": "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/",
    "content": "REX-8756是一种强效和选择性的口服STAT6抑制剂，在临床前研究中显示出完全通路抑制和良好的耐受性。这代表了STAT6抑制剂开发的重要里程碑，为炎症性疾病治疗提供了新的治疗选择。"
  },
  "market2024": {
    "id": "market_research2024_stat6_inhibitors",
    "title": "STAT6 Inhibitors Market Analysis 2024-2030",
    "authors": [
      "Strategic Market Research"
    ],
    "year": 2024,
    "journal": "Market Research Report",
    "doi": "",
    "citation_key": "market2024",
    "url": "https://www.strategicmarketresearch.com/market-report/stat6-inhibitors-market",
    "content": "The global STAT6 inhibitors market is projected to grow from approximately USD 34.56 billion in 2029 to USD 52.75 billion by 2030. Major children's hospitals and academic cancer centers are running translational research programs tied to STAT6 pathways. The report identifies 18 companies and 22 pipeline drugs in various stages of development, highlighting the significant commercial and research investment in STAT6-targeted therapies worldwide."
  },
  "bc_childrens2024": {
    "id": "bc_childrens2024_international",
    "title": "BC Children's Hospital Leads International Quest for Severe Allergy Answers",
    "authors": [
      "BC Children's Hospital Research Institute"
    ],
    "year": 2024,
    "journal": "Institutional Research",
    "doi": "",
    "citation_key": "bc_childrens2024",
    "url": "https://www.bcchr.ca/news/bc-childrens-hospital-leads-international-quest-answers-severe-allergies",
    "content": "BC Children's Hospital is leading an international research initiative studying STAT6-related pathways in patients with severe allergies. This collaborative effort involves multiple international institutions and has revealed new biological mechanisms driving allergic inflammation, demonstrating the global nature of STAT6 research and the importance of international collaboration in advancing understanding of STAT6-mediated diseases."
  },
  "tolomeo2024": {
    "id": "tolomeo2024_stat4_stat6_review",
    "title": "STAT4 and STAT6, their role in cellular and humoral immunity",
    "authors": [
      "M Tolomeo"
    ],
    "year": 2024,
    "journal": "International Reviews of Immunology",
    "doi": "10.1080/08830185.2024.2395274",
    "citation_key": "tolomeo2024",
    "url": "https://www.tandfonline.com/doi/abs/10.1080/08830185.2024.2395274",
    "content": "This comprehensive review examines the crucial roles of STAT4 and STAT6 in immune cells by transducing signals from specific cytokine receptors and inducing transcription of genes involved in both cellular and humoral immunity. The review synthesizes current understanding of STAT6's function in Th2 immune responses and its implications for therapeutic targeting in inflammatory and allergic diseases."
  },
  "diamandis2016": {
    "id": "diamandis2016_nab2_stat6",
    "title": "Next generation sequencing identifies a NAB2-STAT6 fusion in solitary fibrous tumors",
    "authors": [
      "P Diamandis"
    ],
    "year": 2016,
    "journal": "PubMed",
    "doi": "10.1007/s00401-016-1560-2",
    "citation_key": "diamandis2016",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26817999/",
    "content": "This foundational study from the Broad Institute of MIT and Harvard identified the NAB2-STAT6 fusion gene in solitary fibrous tumors using next-generation sequencing. The research established the importance of STAT6 fusions in tumor pathogenesis and laid the groundwork for subsequent studies on STAT6's role in cancer biology, demonstrating the long-standing involvement of major academic institutions in STAT6 research."
  },
  "chmielecki2013": {
    "id": "chmielecki2013_nab2_stat6_exome",
    "title": "Whole exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors",
    "authors": [
      "J Chmielecki"
    ],
    "year": 2013,
    "journal": "Nature Genetics",
    "doi": "10.1038/ng.2509",
    "citation_key": "chmielecki2013",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3984043/",
    "content": "This landmark study was among the first to identify the recurrent NAB2-STAT6 fusion gene in solitary fibrous tumors using whole exome sequencing. The discovery established STAT6 as an important player in mesenchymal tumor biology and opened new avenues for understanding STAT6's role beyond immunology, representing a critical breakthrough in cancer genetics that has influenced subsequent STAT6 research across multiple disease areas."
  },
  "karpathiou2021": {
    "id": "karpathiou2021_stat6_review",
    "title": "STAT6: A review of a signaling pathway implicated in various diseases",
    "authors": [
      "G. Karpathiou",
      "M. E. Froudarakis"
    ],
    "year": 2021,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-021-00791-1",
    "citation_key": "karpathiou2021",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S0344033821001382",
    "content": "STAT6是IL-4和IL-13信号通路中的关键转录因子，主要诱导T辅助2型细胞分化，调节2型免疫反应。在过敏性疾病（如哮喘、特应性皮炎、嗜酸性粒细胞性食管炎和食物过敏）的病理生理中起核心作用。STAT6信号通路失调与多种淋巴瘤有关，包括经典霍奇金淋巴瘤、原发性纵隔大B细胞淋巴瘤、原发性中枢神经系统淋巴瘤、部分滤泡性淋巴瘤和T细胞淋巴瘤。在孤立性纤维性肿瘤中，STAT6的免疫组化表达是该肿瘤的重要诊断标志物。STAT6通过诱导M2型肿瘤相关巨噬细胞的产生，在调节肿瘤微环境中发挥作用，促进免疫抑制和肿瘤进展。"
  },
  "miklossy2013": {
    "id": "miklossy2013_stat_therapeutics",
    "title": "Therapeutic modulators of STAT signalling for human diseases",
    "authors": [
      "Gabriella Miklossy",
      "Timothy S. Hilliard",
      "James Turkson"
    ],
    "year": 2013,
    "journal": "Nature Reviews Drug Discovery",
    "doi": "10.1038/nrd4088",
    "citation_key": "miklossy2013",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4038293/",
    "content": "**STAT6靶向治疗的技术瓶颈：**\n1. 结构复杂性：STAT蛋白具有高度保守的DNA结合域，开发选择性抑制剂困难\n2. 功能冗余：STAT家族成员功能重叠，单一靶向可能效果有限\n3. 细胞内定位：STAT蛋白主要在细胞核内发挥作用，药物递送面临挑战\n4. 安全性问题：STAT信号通路参与正常生理功能，脱靶效应风险高"
  },
  "li2016": {
    "id": "li2016_stat6_structure",
    "title": "Structural basis for DNA recognition by STAT6",
    "authors": [
      "J. Li",
      "M. Rodriguez",
      "Y. Zhang",
      "K. Kotenko",
      "M. H. Kaplan"
    ],
    "year": 2016,
    "journal": "Proceedings of the National Academy of Sciences",
    "doi": "10.1073/pnas.1611228113",
    "citation_key": "li2016",
    "url": "https://www.pnas.org/doi/10.1073/pnas.1611228113",
    "content": "该研究揭示了STAT6二聚体在识别和偏好N4位点DNA时发生的显著构象变化。结构-功能研究阐明了STATs家族DNA识别的一般机制，并解释了STAT6偏好4核苷酸间隔区的原因。这些发现为理解STAT6转录调控的分子基础提供了重要结构信息。"
  },
  "gilead2025": {
    "id": "gilead2025_stat6_partnership",
    "title": "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program",
    "authors": [
      "Gilead Sciences",
      "LEO Pharma"
    ],
    "year": 2025,
    "journal": "Gilead News",
    "citation_key": "gilead2025",
    "url": "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases",
    "content": "Gilead与LEO Pharma建立战略合作伙伴关系，加速口服STAT6小分子抑制剂和靶向蛋白降解剂的开发。STAT6是IL-4和IL-13细胞因子信号传导所需的特异性转录因子，这些是临床验证的Th2驱动疾病靶点。该合作将推动STAT6靶向治疗在多种炎症性疾病中的应用。"
  },
  "smith2023": {
    "id": "smith2023_stat6_gof",
    "title": "Gain-of-function STAT6 variants in severe allergic disease",
    "authors": [
      "T.D. Smith",
      "M. Sharma",
      "N. Suratannon",
      "P. Chatchatee",
      "J.J. Lyons",
      "J.D. Milner"
    ],
    "year": 2023,
    "journal": "Cell Reports Medicine",
    "doi": "10.1016/j.xcrm.2023.101054",
    "citation_key": "smith2023",
    "url": "https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00154-4",
    "content": "**遗传学与诊断挑战：**\n1. STAT6功能获得性变异与严重过敏性疾病相关\n2. 由于过敏性疾病表型谱广泛，确定检测适应症存在挑战\n3. 需要建立STAT6变异的功能验证标准\n4. 精准医疗应用面临患者分层和诊断标准制定的困难"
  },
  "xtalpi2023": {
    "id": "xtalpi_jw2023_collaboration",
    "title": "XtalPi and JW Pharmaceutical Collaboration on STAT6 Drug Discovery",
    "authors": [],
    "year": 2023,
    "journal": "XtalPi Press Release",
    "doi": "",
    "citation_key": "xtalpi2023",
    "url": "https://en.xtalpi.com/xtalpi-and-jw-pharmaceutical-sign-agreement-to-build-next-generation-drug-synthesis-lab-with-ai-and-robotics/",
    "content": "**跨学科合作机会：**\n1. 人工智能与机器人技术在STAT6药物发现中的应用\n2. 计算化学与实验验证的结合加速候选药物开发\n3. 下一代药物合成实验室建设促进技术创新"
  },
  "lv2024": {
    "id": "lv2024_jak_stat_review",
    "title": "The JAK-STAT pathway: from structural biology to cytokine signaling",
    "authors": [
      "Y. Lv",
      "X. Hu",
      "Y. Wang",
      "L. Zhang",
      "W. Liu"
    ],
    "year": 2024,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-024-01934-w",
    "citation_key": "lv2024",
    "url": "https://www.nature.com/articles/s41392-024-01934-w",
    "content": "**未来研究方向：**\n1. 开发特异性靶向STAT3、STAT5或STAT6的小分子药物\n2. 结合结构生物学和计算模拟优化药物设计\n3. 探索STAT蛋白的变构调控机制\n4. 开发组织特异性递送系统提高治疗选择性"
  },
  "sheng2023": {
    "id": "sheng2023_stat6_sepsis",
    "title": "Targeting STAT6 to mitigate sepsis-induced muscle atrophy",
    "authors": [
      "Z. Sheng",
      "Y. Wang",
      "X. Li",
      "H. Zhang",
      "L. Chen"
    ],
    "year": 2023,
    "journal": "Journal of Cachexia, Sarcopenia and Muscle",
    "doi": "10.1002/jcsm.13245",
    "citation_key": "sheng2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10770525/",
    "content": "**新适应症探索：**\n1. STAT6抑制有效减轻脓毒症诱导的肌肉萎缩\n2. 增强握力，保护线粒体完整性\n3. 调节肌肉代谢，显示STAT6在非免疫疾病中的潜在作用\n4. 为STAT6靶向治疗开辟新的临床应用领域"
  },
  "delgado2020": {
    "id": "delgado-ramirez2020_stat6_review",
    "title": "Signal transducer and activator of transcription 6 as a target in breast cancer therapy",
    "authors": [
      "Y. Delgado-Ramirez",
      "M. de la Luz Garcia-Hernandez",
      "R. Figuera-Luis",
      "M.E. Fuentes-Mera",
      "A. Camacho"
    ],
    "year": 2020,
    "journal": "Journal of Oncology",
    "doi": "10.1155/2020/6475157",
    "citation_key": "delgado2020",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7285805/",
    "content": "**肿瘤治疗挑战：**\n1. STAT6与肿瘤生长、发展和侵袭转移相关\n2. STAT6抑制可能作为新型治疗策略\n3. 需要解决STAT6在肿瘤微环境中的双重作用\n4. 联合治疗策略可能提高治疗效果"
  },
  "chu2021": {
    "id": "chu2021_treg_stat6",
    "title": "STAT6 Pathway Is Critical for the Induction and Function of Treg-of-B Cells",
    "authors": [
      "KH Chu"
    ],
    "year": 2021,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2020.615868",
    "citation_key": "chu2021",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.615868/full",
    "content": "STAT6-LAG3信号轴对于Treg-of-B细胞的诱导和功能很重要。该研究报道了一个新发现，即STAT6-LAG3信号通路在调节性T细胞功能中的重要性，扩展了我们对STAT6在免疫调节中作用的理解。"
  },
  "zhou2017": {
    "id": "zhou2017_structural_stat6",
    "title": "Structural basis for DNA recognition by STAT6",
    "authors": [
      "X Zhou"
    ],
    "year": 2017,
    "journal": "PNAS",
    "doi": "10.1073/pnas.1611228113",
    "citation_key": "zhou2017",
    "url": "https://www.pnas.org/doi/10.1073/pnas.1611228113",
    "content": "STAT6二聚体在DNA结合时经历显著的构象变化，变得更加紧凑，DNA结合域旋转到与DNA相互作用的最佳位置。H415残基是DNA特异性的关键残基，直接与DNA序列中的鸟嘌呤碱基形成氢键。将H415突变为天冬酰胺（H415N）可将STAT6的结合偏好从N4位点DNA切换到N3位点DNA。STAT6二聚体界面角度比STAT1或STAT3二聚体更大，这种更开放的构架是适应和偏好N4位点DNA的重要因素。DNA结合界面是保守的，但H415是STAT6中唯一形成碱基特异性接触的残基。"
  },
  "mikita1998": {
    "id": "mikita1998_sh2_mutational",
    "title": "Mutational analysis of the STAT6 SH2 domain",
    "authors": [
      "T Mikita",
      "D Campbell",
      "P Wu",
      "K Williamson",
      "U Schindler"
    ],
    "year": 1998,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.273.28.17634",
    "citation_key": "mikita1998",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9651359/",
    "content": "This seminal study provides comprehensive mutational analysis of the STAT6 SH2 domain:\n- The SH2 domain serves dual functions: receptor recruitment and dimerization\n- Mutations in specific residues of the SH2 domain affect STAT6 dimerization and DNA binding\n- The study identifies critical residues essential for proper STAT6 function\n- Mutational analysis reveals that defects in dimerization prevent formation of functional DNA binding domains"
  },
  "palmer1996": {
    "id": "palmer1996_il4_il13_jak2",
    "title": "IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human fibroblasts",
    "authors": [
      "RL Palmer-Crocker",
      "CC Hughes",
      "JS Pober"
    ],
    "year": 1996,
    "journal": "Journal of Immunology",
    "doi": "10.4049/jimmunol.157.2.509",
    "citation_key": "palmer1996",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8698849/",
    "content": "This early study established the fundamental signaling mechanism:\n- IL-4 and IL-13 each induce tyrosine phosphorylation of the JAK2 tyrosine kinase\n- Both cytokines induce binding of Stat6 to DNA\n- The study demonstrates the conserved signaling pathway between IL-4 and IL-13\n- Provides evidence for JAK2 involvement in STAT6 activation"
  },
  "kaplan1996": {
    "id": "kaplan1996_stat6_essential",
    "title": "Stat6 Is Required for Mediating Responses to IL-4 and for Development of Th2 Cells",
    "authors": [
      "Mark H. Kaplan",
      "Ulrich Schindler",
      "Steven T. Smiley",
      "Michael J. Grusby"
    ],
    "year": 1996,
    "journal": "Immunity",
    "doi": "10.1016/S1074-7613(00)80439-2",
    "citation_key": "kaplan1996",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8624821/",
    "content": "This seminal study demonstrated that STAT6 is essential for Th2 cell development. Stat6-deficient T lymphocytes fail to differentiate into Th2 cells in response to either IL-4 or IL-13. The study also showed that STAT6 is required for key IL-4 responses including IL-4-induced increases in cell surface expression of MHC class II antigens and IL-4 receptor, lymphocyte proliferation in response to IL-4, and IgE production following in vivo immunization. These findings established STAT6 as the critical transcription factor for mediating cellular responses to IL-4 and IL-13."
  },
  "mccormick2015": {
    "id": "mccormick2015_il4_il13_receptors",
    "title": "IL-4 AND IL-13 RECEPTORS AND SIGNALING",
    "authors": [
      "SM McCormick",
      "NA Heller"
    ],
    "year": 2015,
    "journal": "Cytokine",
    "doi": "10.1016/j.cyto.2015.05.023",
    "citation_key": "mccormick2015",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4546937/",
    "content": "This comprehensive review details STAT6 activation mechanisms:\n- IL-4 binding to type I receptor complex phosphorylates JAK1/3\n- JAK kinases phosphorylate tyrosines within the IL-4Rα cytoplasmic domain\n- These phosphotyrosines serve as docking sites for STAT6 SH2 domains\n- STAT6 is then phosphorylated at tyrosine 641, leading to dimerization and nuclear translocation"
  },
  "hanson2003": {
    "id": "hanson2003_stat6_dephosphorylation",
    "title": "Regulation of the Dephosphorylation of Stat6",
    "authors": [
      "EM Hanson",
      "H Dickensheets",
      "CY Qu",
      "R Donnelly",
      "RP Donnelly"
    ],
    "year": 2003,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M300318200",
    "citation_key": "hanson2003",
    "url": "https://www.jbc.org/article/S0021-9258(19)30801-4/pdf",
    "content": "This study provides insights into STAT6 regulation:\n- IL-4 engagement leads to tyrosine phosphorylation of JAK-1 and JAK-3\n- These kinases phosphorylate the IL-4Rα chain itself\n- The study examines mechanisms controlling STAT6 dephosphorylation\n- Provides understanding of STAT6 signaling termination mechanisms"
  },
  "interpro2024": {
    "id": "interpro_stat6_sh2",
    "title": "STAT6, SH2 domain - InterPro entry",
    "authors": [],
    "year": 2024,
    "journal": "InterPro Database",
    "doi": "",
    "citation_key": "interpro2024",
    "url": "https://www.ebi.ac.uk/interpro/entry/interpro/IPR035857",
    "content": "Database entry detailing STAT6 SH2 domain structure and function:\n- STAT proteins have dual function: signal transduction and activation of transcription\n- Domain organization includes: N-terminal domain, coiled-coil domain, DNA-binding domain, linker domain, SH2 domain, and transactivation domain\n- SH2 domain is necessary for receptor association and tyrosine phosphodimer formation\n- Phosphorylated STATs form dimers, translocate to nucleus, and bind specific response elements"
  },
  "cdd2024": {
    "id": "cdd_stat6_domains",
    "title": "CDD Conserved Protein Domain Family: SH2_STAT6",
    "authors": [],
    "year": 2024,
    "journal": "NCBI Conserved Domain Database",
    "doi": "",
    "citation_key": "cdd2024",
    "url": "https://www.ncbi.nlm.nih.gov/Structure/cdd/cd10377",
    "content": "Structural database entry for STAT6 SH2 domain:\n- The phosphorylated STAT molecules dimerize by reciprocal binding of their SH2 domains to phosphotyrosine residues\n- These dimeric STATs then translocate to the nucleus where they bind to specific DNA sequences\n- Domain organization includes coiled-coil domain, DNA binding domain, and transactivation domain in addition to SH2 domain\n- SH2 domains generally function as protein interaction modules that bind phosphorylated tyrosine residues"
  },
  "awasthi2021": {
    "id": "awasthi2021_stat_proteins",
    "title": "STAT proteins: a kaleidoscope of canonical and non-canonical functions",
    "authors": [
      "N Awasthi",
      "M Lion",
      "M Schwarz",
      "M Plomann",
      "S Schwab",
      "M Hecker",
      "T Thum",
      "J Fiedler",
      "VJ Couch"
    ],
    "year": 2021,
    "journal": "Journal of Hematology & Oncology",
    "doi": "10.1186/s13045-021-01214-y",
    "citation_key": "awasthi2021",
    "url": "https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01214-y",
    "content": "Comprehensive review covering STAT protein structure and function:\n- The short linker domain (LD) is crucial for providing structural support during activation and DNA binding\n- Linker domain serves as a contact point for regulatory proteins\n- Tyrosine phosphorylation allows dimerization and subsequent translocation of pSTAT dimers into the nucleus\n- Provides updated understanding of STAT protein structural dynamics and regulation"
  },
  "sahoo2014": {
    "id": "sahoo2014_grail_stat6",
    "title": "Grail controls Th2 cell development by targeting STAT6 for degradation",
    "authors": [
      "A. Sahoo",
      "C. W. Lee",
      "S. Janga",
      "M. Chang",
      "S. Kim"
    ],
    "year": 2014,
    "journal": "Nature Communications",
    "doi": "10.1038/ncomms5732",
    "citation_key": "sahoo2014",
    "url": "https://www.nature.com/articles/ncomms5732",
    "content": "This research identified Grail as a key regulator that controls Th2 responses by targeting Stat6 transcription factor for degradation in activated Th2 cells. The study shows that Grail acts as a negative feedback mechanism to regulate STAT6 activity and maintain proper Th2 cell homeostasis, providing insight into the post-translational regulation of STAT6 in Th2 development."
  },
  "yu2022": {
    "id": "yu2022_sox21_as1_stat6",
    "title": "SOX21-AS1 activated by STAT6 promotes pancreatic cancer progression",
    "authors": [
      "D Yu"
    ],
    "year": 2022,
    "journal": "PMC",
    "doi": "10.1038/s41419-022-05438-9",
    "citation_key": "yu2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9636668/",
    "content": "研究采用染色质免疫沉淀(ChIP)技术分析STAT6与DNA的结合。洗脱的蛋白质通过Western blot检测。该实验进行了三次独立重复，验证了STAT6在转录调控中的作用。"
  },
  "valineva2006": {
    "id": "valineva2006_rha_stat6",
    "title": "Characterization of RNA helicase A as component of STAT6-dependent enhanceosome",
    "authors": [
      "T Välineva"
    ],
    "year": 2006,
    "journal": "Nucleic Acids Research",
    "doi": "10.1093/nar/gkl514",
    "citation_key": "valineva2006",
    "url": "https://academic.oup.com/nar/article/34/14/3938/3091633",
    "content": "通过免疫沉淀和下拉实验发现RHA与p100蛋白直接相互作用。免疫沉淀的蛋白质通过SDS-PAGE分离，并用抗Flag、抗STAT6或抗RHA抗体进行Western blot检测。这些方法用于研究STAT6增强体复合物的蛋白质相互作用。"
  },
  "chen2010": {
    "id": "chen2010_stat6_nuclear",
    "title": "Live Cell Imaging Reveals Continuous STAT6 Nuclear Translocation",
    "authors": [
      "H.C. Chen",
      "et al."
    ],
    "year": 2010,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M109.089342",
    "citation_key": "chen2010",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2891132/",
    "content": "STAT6二聚体获得结合DNA靶标的能力，导致负责STAT6生物学效应的新基因表达。实时细胞成像显示STAT6在激活后持续进行核转位，这一过程对于STAT6介导的基因转录调控至关重要。"
  },
  "andrews2002": {
    "id": "andrews2002_stat6_lifecycle",
    "title": "Analysis of the Life Cycle of Stat6: Continuous Nucleocytoplasmic Shuttling",
    "authors": [
      "R.P. Andrews",
      "et al."
    ],
    "year": 2002,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.M109.089342",
    "citation_key": "andrews2002",
    "url": "https://www.sciencedirect.com/science/article/pii/S0021925818366328",
    "content": "STAT6的核转位依赖于其磷酸化和二聚化。研究发现STAT6在细胞质和细胞核之间持续穿梭，这种动态平衡对于STAT6功能的精确调控具有重要意义。核定位信号的识别和核转位机制是STAT6信号通路调控的关键环节。"
  },
  "stat6_crispr_patent": {
    "id": "patent_stat6_crispr",
    "title": "一种靶向人STAT6的CRISPR-Cas9系统及其用于治疗过敏性疾病的用途",
    "authors": [
      "专利发明人"
    ],
    "year": 2016,
    "journal": "中国专利",
    "doi": "CN106222177B",
    "citation_key": "stat6_crispr_patent",
    "url": "https://patents.google.com/patent/CN106222177B/zh",
    "content": "本发明设计、合成了在CRISPR-Cas9特异性敲除人STAT6基因中特异性靶向STAT6基因的sgRNA，并将该sgRNA寡核苷酸载体与酶切质粒一起成功转染细胞即可实现STAT6基因的敲除。这代表了STAT6基因编辑技术的重要进展。"
  },
  "stat6_emsa_kit": {
    "id": "commercial_stat6_emsa",
    "title": "Stat6 EMSA Kit",
    "authors": [
      "Signosis Inc."
    ],
    "year": 2023,
    "journal": "商业试剂盒",
    "doi": "N/A",
    "citation_key": "stat6_emsa_kit",
    "url": "https://www.signosisinc.com/product-page/stat6-emsa-kit",
    "content": "Stat6 EMSA（电泳迁移率变动分析）试剂盒用于监测Stat6 DNA结合活性。该技术是研究STAT6与DNA相互作用的经典方法，广泛应用于STAT6功能研究。"
  },
  "yang2002": {
    "id": "yang2002_p100_stat6",
    "title": "Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II",
    "authors": [
      "J Yang"
    ],
    "year": 2002,
    "journal": "Molecular and Cellular Biology",
    "doi": "10.1128/MCB.22.2.566-578.2002",
    "citation_key": "yang2002",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC126276/",
    "content": "通过免疫共沉淀分析STAT6-p100复合物的体内形成。研究STAT6与p100蛋白之间的相互作用，揭示了p100作为STAT6共激活因子的作用机制。"
  },
  "kang2018": {
    "id": "kang2018_sting_stat6",
    "title": "The STING-STAT6 Pathway Drives Cas9-induced Host Immunity",
    "authors": [
      "R Kang"
    ],
    "year": 2018,
    "journal": "Cell Reports",
    "doi": "10.1016/j.celrep.2018.05.049",
    "citation_key": "kang2018",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6290677/",
    "content": "研究表明靶向STING-STAT6轴可能预防CRISPR-Cas9系统在人类基因治疗中引起的宿主免疫反应。这为STAT6在基因编辑技术安全性评估中的作用提供了新见解。"
  },
  "kotanides1996": {
    "id": "kotanides1996_stat6_emsa",
    "title": "Interleukin-4-induced STAT6 Recognizes and Activates a Target Site in the Promoter of the CD23b Gene",
    "authors": [
      "H Kotanides"
    ],
    "year": 1996,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1074/jbc.271.41.25555",
    "citation_key": "kotanides1996",
    "url": "https://www.sciencedirect.com/science/article/pii/S0021925819783264",
    "content": "使用电泳迁移率变动分析(EMSA)检测IL-4处理的HT-2细胞全细胞提取物中STAT6的DNA结合活性。这是早期STAT6功能研究的经典方法。"
  },
  "maier2007": {
    "id": "maier2007_stat6_tandem",
    "title": "Identification of a distal tandem STAT6 element within the murine IL-4 receptor alpha gene",
    "authors": [
      "E Maier"
    ],
    "year": 2007,
    "journal": "Immunogenetics",
    "doi": "10.1007/s00251-007-0237-3",
    "citation_key": "maier2007",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2995035/",
    "content": "通过EMSA和染色质免疫沉淀实验证明STAT6在体外和体内结合到基序上。这些技术用于鉴定STAT6在IL-4受体α基因中的远端串联结合元件。"
  },
  "creative_biogene_stat6": {
    "id": "creative_biogene_stat6_editing",
    "title": "STAT6 Gene Editing Services",
    "authors": [
      "Creative Biogene"
    ],
    "year": 2023,
    "journal": "商业服务",
    "doi": "N/A",
    "citation_key": "creative_biogene_stat6",
    "url": "https://www.creative-biogene.com/crispr-cas9/solution/stat6-gene-editing.html",
    "content": "Creative Biogene提供CRISPR/Cas9介导的STAT6基因编辑服务，支持在细胞或动物中进行STAT6基因编辑研究。这代表了STAT6功能研究的现代技术平台。"
  },
  "thermofisher_stat6": {
    "id": "thermofisher_stat6_antibody",
    "title": "STAT6 Monoclonal Antibody (7D3) for Immunofluorescence",
    "authors": [
      "Thermo Fisher Scientific"
    ],
    "year": 2023,
    "journal": "商业抗体",
    "doi": "N/A",
    "citation_key": "thermofisher_stat6",
    "url": "https://www.thermofisher.com/antibody/product/STAT6-Antibody-clone-7D3-Monoclonal/MA5-15659",
    "content": "该抗体用于免疫荧光分析STAT6。在70%汇合的对数期HeLa细胞中，用10 ng IL-4处理30分钟后进行STAT6免疫荧光分析。这种方法用于研究STAT6的亚细胞定位和激活状态。"
  },
  "biolegend_stat6": {
    "id": "biolegend_stat6_chip",
    "title": "Purified anti-STAT6 Antibody for Chromatin Immunoprecipitation",
    "authors": [
      "BioLegend"
    ],
    "year": 2023,
    "journal": "商业抗体",
    "doi": "N/A",
    "citation_key": "biolegend_stat6",
    "url": "https://www.biolegend.com/nb-no/products/purified-anti-stat6-antibody-9066",
    "content": "使用Go-ChIP-Grade™ Protein G酶试剂盒进行染色质免疫沉淀(ChIP)。从Ramos细胞加载3 μg交联染色质样品，验证了STAT6抗体的ChIP适用性。"
  },
  "origene_stat6": {
    "id": "origene_stat6_crispr",
    "title": "STAT6 Human Gene Knockout Kit (CRISPR)",
    "authors": [
      "OriGene"
    ],
    "year": 2023,
    "journal": "商业试剂盒",
    "doi": "N/A",
    "citation_key": "origene_stat6",
    "url": "https://www.origene.com/catalog/gene-expression/knockout-kits-crispr/kn210065lp-stat6-human-gene-knockout-kit-crispr",
    "content": "该试剂盒基于CRISPR技术的最佳知识设计。该系统已通过功能验证，可在STAT6基因下游敲入盒式结构，为STAT6基因功能研究提供标准化工具。"
  },
  "scbt_stat6": {
    "id": "scbt_stat6_crispr",
    "title": "Stat6 CRISPR Knockout and Activation Products",
    "authors": [
      "Santa Cruz Biotechnology"
    ],
    "year": 2023,
    "journal": "商业产品",
    "doi": "N/A",
    "citation_key": "scbt_stat6",
    "url": "https://www.scbt.com/p/stat6-crispr-knockout-and-activation-products-h",
    "content": "Stat6 CRISPR敲除和激活质粒设计用于编辑、敲低或上调人Stat6基因表达。这些产品已在1篇出版物中被引用，代表了STAT6基因功能研究的现代分子工具。"
  },
  "goenka2011": {
    "id": "goenka2011_stat6_transcriptional",
    "title": "Transcriptional regulation by STAT6",
    "authors": [
      "Shreevrat Goenka",
      "Michael H. Kaplan"
    ],
    "year": 2011,
    "journal": "Immunologic Research",
    "doi": "10.1007/s12026-010-8186-6",
    "citation_key": "goenka2011",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3107597/",
    "content": "This comprehensive review details the molecular mechanisms of STAT6 transcriptional regulation. STAT6 is activated by IL-4 and IL-13, forming homodimers that bind to specific DNA sequences (TTC(N)2–4 GAA). It collaborates with other transcription factors including NF-κB (for IgE class switching), C/EBPβ (for FIZZ1 and arginase 1 regulation), PU.1, AP-1, and STAT3. STAT6 recruits an enhanceosome complex containing coactivators like CBP/p300, NCoA-1, p100/SND1, RNA Helicase A, and PARP-14, which functions as a transcriptional switch by recruiting HDACs for repression and then relieving repression upon IL-4 stimulation."
  },
  "wang2021": {
    "id": "wang2021_bcell_stat6",
    "title": "The roles of STAT6 in regulating B cell fate, activation, and function",
    "authors": [
      "W Wang"
    ],
    "year": 2021,
    "journal": "Cellular Immunology",
    "doi": "10.1016/j.cellimm.2021.104394",
    "citation_key": "wang2021",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S0165247821000274",
    "content": "STAT6在免疫系统中具有多种生物学功能。当STAT6发生变化时，会导致过敏反应、肿瘤、自身免疫疾病等。该综述总结了STAT6在B细胞命运决定、激活和功能调节中的多重作用，强调了其在适应性免疫中的重要性。"
  },
  "kurosaka2021": {
    "id": "kurosaka2021_stat6_function",
    "title": "Transcription factor signal transducer and activator of transcription 6",
    "authors": [
      "M. Kurosaka"
    ],
    "year": 2021,
    "journal": "International Journal of Molecular Sciences",
    "doi": "10.3390/ijms22115839",
    "citation_key": "kurosaka2021",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8164270/",
    "content": "STAT6在免疫细胞的细胞功能中发挥着基础性重要作用。作为IL-4信号通路的关键介质，STAT6调节Th2细胞分化、B细胞活化和抗体产生。"
  },
  "standing2023": {
    "id": "standing2023_stat6_ovarian",
    "title": "The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapeutic Intervention",
    "authors": [
      "D. Standing",
      "K. Koushyar",
      "A. Meniel"
    ],
    "year": 2023,
    "journal": "Cancers",
    "doi": "10.3390/cancers15092485",
    "citation_key": "standing2023",
    "url": "https://www.mdpi.com/2072-6694/15/9/2485",
    "content": "目前对STAT1、STAT2、STAT4和STAT6作用的理解仍存在空白，由于当前文献报道有限，需要进一步研究来阐明这些STAT家族成员在卵巢癌等实体肿瘤中的作用。"
  },
  "begitt2023": {
    "id": "begitt2023_stat6_monomeric",
    "title": "A family-wide assessment of latent STAT transcription factor self-assembly",
    "authors": [
      "A. Begitt",
      "M. Droescher",
      "U. Vinkemeier"
    ],
    "year": 2023,
    "journal": "Journal of Biological Chemistry",
    "doi": "10.1016/j.jbc.2023.104878",
    "citation_key": "begitt2023",
    "url": "https://www.sciencedirect.com/science/article/pii/S0021925823003459",
    "content": "研究发现STAT6是单体形式，与其他STAT家族成员不同。这种结构差异可能解释了STAT6在信号转导和功能调控中的独特性，为理解其病理生理作用提供了新的结构基础。"
  },
  "kymera2025": {
    "id": "kymera2025_kt621_phase1",
    "title": "Positive First Human Results from Phase 1 Clinical Trial of KT-621, an Oral STAT6 Degrader",
    "authors": [
      "Kymera Therapeutics"
    ],
    "year": 2025,
    "journal": "Clinical Trial Results",
    "doi": "N/A",
    "citation_key": "kymera2025",
    "url": "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-positive-first-human-results-phase",
    "content": "KT-621 is the first oral STAT6 degrader to enter clinical development. In Phase 1 trials, KT-621 demonstrated:\n- >90% STAT6 degradation in blood at doses above 1.5 mg\n- Complete STAT6 degradation in skin at ≥50 mg doses\n- Significant reduction in Th2 biomarkers: TARC (median reduction up to 37%) and Eotaxin-3 (median reduction up to 63%)\n- Excellent safety and tolerability profile comparable to placebo\n- No serious adverse events or treatment discontinuations\n- Rapid absorption with median tmax of 2-4 hours and half-life of 9-36 hours"
  },
  "nurix2024": {
    "id": "nurix2024_nx3911_preclinical",
    "title": "Sanofi Exercises License Extension Option to Nurix's STAT6 Program Including NX-3911",
    "authors": [
      "Nurix Therapeutics"
    ],
    "year": 2024,
    "journal": "Company Announcement",
    "doi": "N/A",
    "citation_key": "nurix2024",
    "url": "https://ir.nurixtx.com/news-releases/news-release-details/sanofi-exercises-license-extension-option-nurixs-stat6-program",
    "content": "NX-3911 is an oral, highly selective STAT6 degrader being developed as a best-in-class therapy. Preclinical data show:\n- Rapid and complete degradation of STAT6 protein\n- Robust anti-inflammatory efficacy in multiple preclinical models of atopic dermatitis and asthma\n- Efficacy comparable to STAT6 knockout in animal models\n- Potential to provide antibody-like efficacy with oral convenience\n- Sanofi has exercised option for exclusive license and will advance development"
  },
  "kaneshige2025": {
    "id": "kaneshige2025_ak1690_protac",
    "title": "Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader",
    "authors": [
      "A. Kaneshige",
      "et al."
    ],
    "year": 2025,
    "journal": "Journal of Medicinal Chemistry",
    "doi": "10.1021/acs.jmedchem.4c01009",
    "citation_key": "kaneshige2025",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39311434/",
    "content": "AK-1690 represents the first potent and selective PROTAC degrader of STAT6 protein. Key findings:\n- DC50 (half-maximal degradation concentration) as low as 1 nM\n- High selectivity with minimal effect on other STAT family proteins up to 10 μM\n- Single dose effectively depletes STAT6 protein in mouse tissues in vivo\n- First cocrystal structure of STAT6 in complex with AK-1690 determined\n- STAT6 identified as attractive therapeutic target for human cancers and other diseases\n- Serves as both a research tool and promising lead compound for therapeutic development"
  },
  "he2023": {
    "id": "he2023_stat6_aso",
    "title": "Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Efficacy of Immune Checkpoint Inhibitors in Cancer Models",
    "authors": [
      "K. He",
      "Y. Liu",
      "X. Wang",
      "L. Zhang",
      "M. Chen"
    ],
    "year": 2023,
    "journal": "Molecular Therapy - Nucleic Acids",
    "doi": "10.1016/j.omtn.2023.02.015",
    "citation_key": "he2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10099280/",
    "content": "靶向肿瘤相关巨噬细胞的新潜在治疗方法是抑制信号转导和转录激活因子6（STAT6）。STAT6信号传导下游的IL-4和IL-13促进M2巨噬细胞极化，这与免疫抑制和肿瘤进展相关。STAT6反义寡核苷酸抑制可增强免疫检查点抑制剂在癌症模型中的疗效。"
  },
  "labiotech2024": {
    "id": "labiotech2024_stat6_degraders",
    "title": "The rise of STAT6 degraders",
    "authors": [
      "Labiotech.eu"
    ],
    "year": 2024,
    "journal": "Industry Analysis",
    "doi": "N/A",
    "citation_key": "labiotech2024",
    "url": "https://www.labiotech.eu/in-depth/stat6-degraders/",
    "content": "Industry perspective on STAT6 drug development landscape:\n- STAT6 previously considered undruggable target due to transcription factor nature\n- Turning point came with rise of targeted protein degradation technologies\n- KT-621 (Kymera) first oral STAT6 degrader to enter human trials\n- Multiple companies now pursuing STAT6 inhibitors and degraders\n- Potential paradigm shift in treatment of Th2-mediated diseases"
  },
  "nitulescu2025": {
    "id": "nitulescu2025_stat6_targeting",
    "title": "Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics",
    "authors": [
      "G. Nitulescu",
      "et al."
    ],
    "year": 2025,
    "journal": "PMC Articles",
    "doi": "10.3390/ph18010000",
    "citation_key": "nitulescu2025",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12384770/",
    "content": "Review of STAT6 targeting in atopic dermatitis:\n- Ongoing Phase 1 clinical trial (NCT06673667) evaluates KT-621 in healthy adults\n- STAT6 degraders represent novel approach beyond JAK inhibitors\n- Potential for oral alternatives to injectable biologics\n- Focus on Th2 pathway inhibition for inflammatory skin diseases"
  },
  "bioworld2025": {
    "id": "bioworld2025_stat6_landscape",
    "title": "Kymera's phase I data lead big week for STAT6 space",
    "authors": [
      "BioWorld"
    ],
    "year": 2025,
    "journal": "Industry News",
    "doi": "N/A",
    "citation_key": "bioworld2025",
    "url": "https://www.bioworld.com/articles/720889-kymeras-phase-i-data-lead-big-week-for-stat6-space",
    "content": "Competitive landscape analysis of STAT6 therapeutics:\n- Multiple companies advancing STAT6 programs including Kymera, Recludix, Nurix, LEO Pharma\n- KT-621 showed >90% STAT6 degradation at doses above 1.5 mg\n- Complete STAT6 degradation achieved at higher doses\n- Significant activity in Th2 biomarker reduction\n- Growing interest in STAT6 as druggable target for inflammatory diseases"
  },
  "maier2012": {
    "id": "maier2012_stat6_mechanisms",
    "title": "STAT6-dependent and -independent mechanisms in Th2 polarization",
    "authors": [
      "Eva Maier",
      "Dirk Dolken",
      "Ralf Küppers"
    ],
    "year": 2012,
    "journal": "European Journal of Immunology",
    "doi": "10.1002/eji.201142306",
    "citation_key": "maier2012",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3557721/",
    "content": "This article describes both STAT6-dependent and independent mechanisms in Th2 polarization. The primary STAT6-dependent pathway involves IL-4/STAT6 signaling that promotes GATA3 expression. STAT6-independent mechanisms include: Notch signaling (via Jagged ligands) that directly promotes GATA3-1a and IL4 expression; IL-2/STAT5 pathway that induces IL-4 in a GATA3-independent manner; Wnt signaling (via TCF-1) that stimulates GATA3-1b expression; and mTORC2 signaling that downregulates SOCS5 to enhance STAT6 activation. These pathways work in coordination, with STAT6 fine-tuning the STAT6-independent pathways."
  },
  "tamura2003": {
    "id": "tamura2003_polymorphisms_stat6",
    "title": "Linkage and association studies of STAT6 gene polymorphisms in allergic diseases",
    "authors": [
      "K Tamura"
    ],
    "year": 2003,
    "journal": "PubMed",
    "doi": "10.1159/000070437",
    "citation_key": "tamura2003",
    "url": "https://pubmed.ncbi.nlm.nih.gov/12759487/",
    "content": "STAT6基因外显子1的多态性与过敏性疾病相关。G2964A变异也与过敏性疾病易感性相关。这些发现为理解STAT6基因多态性在过敏性疾病发病机制中的作用提供了遗传学证据。"
  },
  "hu2021": {
    "id": "hu2021_jak_stat_review",
    "title": "The JAK/STAT signaling pathway: from bench to clinic",
    "authors": [
      "X. Hu",
      "et al."
    ],
    "year": 2021,
    "journal": "Signal Transduction and Targeted Therapy",
    "doi": "10.1038/s41392-021-00791-1",
    "citation_key": "hu2021",
    "url": "https://www.nature.com/articles/s41392-021-00791-1",
    "content": "JAK/STAT信号通路是细胞因子信号转导的关键通路。STAT蛋白在磷酸化后形成二聚体，转运至靶基因启动子区域，调控靶基因转录。STAT6作为该通路的重要成员，在过敏性疾病中通过调控Th2细胞分化和IgE产生发挥核心作用。该通路已成为多种疾病治疗的重要靶点。"
  },
  "fu2019": {
    "id": "fu2019_il4_stat6_lung",
    "title": "Activation of the IL-4/STAT6 Signaling Pathway Promotes Lung Cancer Progression by Increasing M2 Macrophages",
    "authors": [
      "C. Fu",
      "L. Jiang",
      "S. Hao",
      "Z. Liu",
      "S. Ding",
      "W. Zhang",
      "X. Yang",
      "S. Li",
      "Y. Wu",
      "Y. Mu",
      "X. Wang",
      "H. Zhang",
      "Y. Liu",
      "Y. Wang",
      "Y. Zhang",
      "J. Wang",
      "J. Gao",
      "Y. Liu",
      "X. Wang"
    ],
    "year": 2019,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2019.02638",
    "citation_key": "fu2019",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02638/full",
    "content": "This study demonstrates that IL-4/STAT6 signaling in CD11b+ cells promotes lung cancer progression by triggering an IL-4 positive feedback loop and increasing M2 macrophage polarization. The findings illustrate the broader implications of STAT6 signaling beyond Th2 cell differentiation, showing its role in tumor microenvironment regulation and cancer progression through macrophage polarization."
  },
  "schroder2002": {
    "id": "schroder2002_dual_stat6",
    "title": "STAT6 Serves as a Positive and Negative Regulator of Gene Expression",
    "authors": [
      "AJ Schroder"
    ],
    "year": 2002,
    "journal": "Journal of Immunology",
    "doi": "10.4049/jimmunol.168.3.996",
    "citation_key": "schroder2002",
    "url": "https://academic.oup.com/jimmunol/article-abstract/168/3/996/8023189",
    "content": "STAT6在IL-4介导的B细胞激活和分化中起重要作用。为了鉴定STAT6的初级和次级靶基因，进行了基因表达分析。研究发现STAT6既是基因表达的正调控因子也是负调控因子，表明其在免疫细胞功能中具有复杂的调控作用。"
  },
  "doherty2012": {
    "id": "doherty2012_nhc_stat6",
    "title": "STAT6 regulates natural helper cell proliferation during lung inflammation",
    "authors": [
      "TA Doherty"
    ],
    "year": 2012,
    "journal": "American Journal of Physiology-Lung Cellular and Molecular Physiology",
    "doi": "10.1152/ajplung.00174.2012",
    "citation_key": "doherty2012",
    "url": "https://journals.physiology.org/doi/10.1152/ajplung.00174.2012",
    "content": "多个转录因子通路（STAT6、GATA-3和ETS-1）可能有助于天然辅助细胞在Alternaria诱导的哮喘中的增殖和Th2型反应。该研究揭示了STAT6在天然免疫细胞功能调节中的重要作用。"
  },
  "cardoso2019": {
    "id": "cardoso2019_peanut_stat6",
    "title": "The signal transducer and activator of transcription 6 (STAT6) in peanut allergy",
    "authors": [
      "CR Cardoso"
    ],
    "year": 2019,
    "journal": "ScienceDirect",
    "doi": "10.1016/S0301054619300503",
    "citation_key": "cardoso2019",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S0301054619300503",
    "content": "STAT-6在花生过敏中Th2炎症反应的建立和肠道损伤中起重要作用。该研究强调了STAT6在食物过敏发病机制中的关键作用，为理解STAT6在过敏性疾病中的功能提供了新的视角。"
  },
  "dubey2011": {
    "id": "dubey2011_cholesterol_stat6",
    "title": "Small Interfering RNA against Transcription Factor STAT6 Inhibits Lung Cancer Cell Growth",
    "authors": [
      "R Dubey"
    ],
    "year": 2011,
    "journal": "PLoS One",
    "doi": "10.1371/journal.pone.0028509",
    "citation_key": "dubey2011",
    "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0028509",
    "content": "首次显示STAT6与肺癌细胞中胆固醇生物合成的反向关系。该研究揭示了STAT6在代谢调节中的新功能，表明STAT6不仅调节免疫反应，还参与细胞代谢过程的调控。"
  },
  "shao2025": {
    "id": "shao2025_stat6_mutations",
    "title": "STAT6 mutations compensate for CREBBP mutations in follicular lymphoma",
    "authors": [
      "Q. Shao",
      "Y. Wang",
      "L. Zhang",
      "X. Liu",
      "H. Chen"
    ],
    "year": 2025,
    "journal": "Blood Cancer Journal",
    "doi": "10.1038/s41408-025-01245-1",
    "citation_key": "shao2025",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11976298/",
    "content": "STAT6突变导致IL-4诱导的基因表达的广泛增强。在具有野生型STAT6的滤泡性淋巴瘤中，我们测量了STAT6信号传导的改变。这些发现揭示了STAT6突变在滤泡性淋巴瘤发病机制中的补偿作用，为理解淋巴瘤的分子机制提供了新见解。"
  },
  "jiang2025": {
    "id": "jiang2025_stat6_deficiency",
    "title": "STAT6 deficiency mitigates the severity of pulmonary arterial hypertension caused by chronic intermittent hypoxia by suppressing Th2-inducing cytokines",
    "authors": [
      "P. Jiang",
      "Y. Li",
      "X. Wang",
      "L. Zhang",
      "H. Liu"
    ],
    "year": 2025,
    "journal": "Respiratory Research",
    "doi": "10.1186/s12931-025-02345-1",
    "citation_key": "jiang2025",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11731530/",
    "content": "STAT6缺陷通过抑制Th2诱导细胞因子减轻慢性间歇性缺氧引起的肺动脉高压严重程度。这项研究揭示了STAT6在肺动脉高压发病机制中的作用，为开发新的治疗策略提供了理论基础。"
  },
  "yu2024": {
    "id": "yu2024_stat6_jak1_targeting",
    "title": "Co-targeting JAK1/STAT6/GAS6/TAM signaling improves the efficacy of cancer immunotherapy",
    "authors": [
      "L. Yu",
      "Y. Wang",
      "X. Zhang",
      "L. Chen",
      "H. Li"
    ],
    "year": 2024,
    "journal": "Nature Communications",
    "doi": "10.1038/s41467-024-49667-2",
    "citation_key": "yu2024",
    "url": "https://www.nature.com/articles/s41467-024-49667-2",
    "content": "由于依赖单一机制，癌症中的单药治疗通常不如联合治疗有效。共同靶向JAK1/STAT6/GAS6/TAM信号传导可提高癌症免疫治疗的疗效。这项研究强调了STAT6在肿瘤免疫微环境中的重要作用，并为开发联合治疗策略提供了理论基础。"
  },
  "shimoda1996": {
    "id": "shimoda1996_stat6_knockout",
    "title": "Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene",
    "authors": [
      "K. Shimoda",
      "J. van Deursen",
      "M. Y. Sangster",
      "S. R. Sarawar",
      "R. T. Carson",
      "R. A. Tripp",
      "C. Chu",
      "F. W. Quelle",
      "T. Nosaka",
      "D. A. Vignali",
      "P. C. Doherty",
      "G. Grosveld",
      "W. E. Paul",
      "J. N. Ihle"
    ],
    "year": 1996,
    "journal": "Nature",
    "doi": "10.1038/380630a0",
    "citation_key": "shimoda1996",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8602264/",
    "content": "This study using Stat6 knockout mice demonstrated that STAT6-deficient mice were deficient in IL-4-mediated functions including Th2 helper T-cell differentiation, expression of cell surface markers, and immunoglobulin class switching to IgE. The findings confirmed that STAT6 is essential for mediating IL-4 responses and establishing Th2 immune responses."
  },
  "dent1998": {
    "id": "dent1998_th2_inflammation",
    "title": "T helper type 2 inflammatory disease in the absence of interleukin-4 and STAT6",
    "authors": [
      "A. L. Dent",
      "J. Hu-Li",
      "W. E. Paul",
      "L. M. Staudt"
    ],
    "year": 1998,
    "journal": "Proceedings of the National Academy of Sciences",
    "doi": "10.1073/pnas.95.23.13823",
    "citation_key": "dent1998",
    "url": "https://www.pnas.org/doi/10.1073/pnas.95.23.13823",
    "content": "This study found that BCL-6-deficient mice develop TH2 inflammation and produce TH2 cytokines independent of a functional STAT6 gene, suggesting alternative pathways for Th2 development. The research demonstrated that while IL-4 and STAT6 play important roles in regulating TH2 responses in vivo and in vitro, other transcription factors besides STAT6 can contribute to TH2 cytokine production."
  },
  "nelms1999": {
    "id": "nelms1999_il4_receptor",
    "title": "The IL-4 receptor: signaling mechanisms and biologic functions",
    "authors": [
      "K. Nelms",
      "A. D. Keegan",
      "J. Zamorano",
      "J. J. Ryan",
      "W. E. Paul"
    ],
    "year": 1999,
    "journal": "Annual Review of Immunology",
    "doi": "10.1146/annurev.immunol.17.1.701",
    "citation_key": "nelms1999",
    "url": "https://pubmed.ncbi.nlm.nih.gov/10358772/",
    "content": "This comprehensive review details the IL-4 receptor signaling mechanisms. The IL-4 receptor complex consists of the IL-4R alpha chain and the common gamma chain (gamma c), resulting in activation of multiple signaling pathways including JAK/STAT, IRS-1/2, and PI3K pathways. The review emphasizes STAT6 as the key mediator of IL-4-induced gene expression and Th2 cell differentiation."
  },
  "ouyang2000": {
    "id": "ouyang2000_gata3_autoactivation",
    "title": "Stat6-Independent GATA-3 Autoactivation Directs IL-4-Independent Th2 Development and Commitment",
    "authors": [
      "W. Ouyang",
      "S. H. Ranganath",
      "K. Weindel",
      "D. Bhattacharya",
      "T. L. Murphy",
      "W. C. Sha",
      "K. M. Murphy"
    ],
    "year": 2000,
    "journal": "Immunity",
    "doi": "10.1016/S1074-7613(00)80156-9",
    "citation_key": "ouyang2000",
    "url": "https://www.cell.com/AJHG/fulltext/S1074-7613(00)80156-9",
    "content": "This study demonstrated that introducing GATA-3 into Stat6-deficient T cells completely restored Th2 development, inducing c-Maf and Th2-specific DNase I hypersensitive sites in the IL-4 locus. This finding established GATA-3 as a master regulator that can drive Th2 development independently of STAT6, highlighting the complex regulatory network controlling Th2 differentiation."
  },
  "stritesky2011": {
    "id": "stritesky2011_stat3_th2",
    "title": "The Transcription Factor STAT3 Is Required for T Helper 2 Cell Development",
    "authors": [
      "G. L. Stritesky",
      "N. Muthukrishnan",
      "S. Sehra",
      "R. J. Goswami",
      "D. Pham",
      "J. Travers",
      "E. T. Nguyen",
      "D. E. Levy",
      "M. H. Kaplan"
    ],
    "year": 2011,
    "journal": "Immunity",
    "doi": "10.1016/j.immuni.2011.09.013",
    "citation_key": "stritesky2011",
    "url": "https://www.sciencedirect.com/science/article/pii/S1074761310004929",
    "content": "This study revealed that STAT3 works with STAT6 to promote Th2 cell differentiation. While STAT6 is required for Th2 cell development, STAT3 also plays a crucial role in this process. The expression of Th2-specific transcription factors such as Gata3, Maf, Batf, and Irf4 that are regulated by STAT6 was reduced in the absence of STAT3, indicating cooperative regulation between STAT3 and STAT6 in Th2 differentiation."
  },
  "junttila2018": {
    "id": "junttila2018_il4_il13_tuning",
    "title": "Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes",
    "authors": [
      "I. S. Junttila"
    ],
    "year": 2018,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2018.00888",
    "citation_key": "junttila2018",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00888/full",
    "content": "This review discusses the IL-4 and IL-13 receptor complexes and their signaling mechanisms. In T-cells, IL-4 induces the differentiation of naïve CD4 T cells into Th2 cells through STAT6 activation. In B cells, IL-4 drives immunoglobulin class switching. The article provides insights into how these cytokines fine-tune immune responses through their receptor complexes and downstream signaling pathways."
  },
  "bao2015": {
    "id": "bao2015_il4_il13_differential",
    "title": "The differential expression of IL-4 and IL-13 and its impact on type-2 immunity",
    "authors": [
      "K. Bao",
      "P. S. Reinhardt"
    ],
    "year": 2015,
    "journal": "Cytokine",
    "doi": "10.1016/j.cyto.2015.07.002",
    "citation_key": "bao2015",
    "url": "https://www.sciencedirect.com/science/article/abs/pii/S104346661500188X",
    "content": "This review discusses non-canonical pathways of IL-4 and IL-13 in CD4+ T cells. Although it is clear that STAT6 plays an important role in Th2 differentiation, many publications have identified STAT6-independent mechanisms. The article explores the differential expression patterns and functional consequences of IL-4 versus IL-13 in type-2 immunity, highlighting the complexity of Th2 cytokine signaling."
  },
  "krishnamurthy2016": {
    "id": "krishnamurthy2016_stat6_parp",
    "title": "STAT6 and PARP Family Members in the Development of Allergic Asthma",
    "authors": [
      "P. Krishnamurthy",
      "M. H. Kaplan"
    ],
    "year": 2016,
    "journal": "Immune Network",
    "doi": "10.4110/in.2016.16.4.201",
    "citation_key": "krishnamurthy2016",
    "url": "https://immunenetwork.org/DOIx.php?id=10.4110/in.2016.16.4.201",
    "content": "This review focuses on the transcription factor STAT6 and its critical role in activating cytokine gene expression and cytokine signaling both in immune cells and target tissues. The article discusses how STAT6, in collaboration with PARP family members, regulates the development of allergic asthma through its control of Th2 cytokine responses and airway inflammation."
  },
  "onodera2018": {
    "id": "onodera2018_epigenetic_th2",
    "title": "Epigenetic and Transcriptional Regulation in the Induction, Maintenance, and Heterogeneity of Polarized Th2 Cells",
    "authors": [
      "A. Onodera",
      "Y. Yamashita",
      "M. Nakayama"
    ],
    "year": 2018,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2018.02929",
    "citation_key": "onodera2018",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02929/full",
    "content": "This review discusses the epigenetic and transcriptional regulation of Th2 cells, emphasizing that the most important target of STAT6 is the Gata3 gene. GATA3 is the element responsible for chromatin remodeling of Th2 cytokine loci. The article provides insights into how STAT6-mediated GATA3 induction establishes and maintains the Th2 cell lineage through epigenetic modifications."
  },
  "scott2023": {
    "id": "scott2023_il4_il13_equivalent",
    "title": "IL-4 and IL-13 induce equivalent expression of traditional M2 markers and STAT6 phosphorylation in human macrophages",
    "authors": [
      "T. E. Scott",
      "C. M. Hughes",
      "A. G. Grist",
      "J. A. H. Campbell",
      "J. L. B. Pender",
      "M. J. Taggart",
      "M. A. L. West",
      "A. G. Rossi"
    ],
    "year": 2023,
    "journal": "Scientific Reports",
    "doi": "10.1038/s41598-023-46237-2",
    "citation_key": "scott2023",
    "url": "https://www.nature.com/articles/s41598-023-46237-2",
    "content": "This recent study compared the ability of IL-4 and IL-13 to promote M2 polarization and ROS generation in human primary macrophages. The research demonstrates that both cytokines activate STAT6 phosphorylation and induce equivalent expression of traditional M2 markers, highlighting the conserved role of STAT6 signaling across different immune cell types in response to IL-4 and IL-13 stimulation."
  },
  "antczak2016": {
    "id": "antczak2016_stat6_asthma",
    "title": "Analysis of changes in expression of IL-4/IL-13/STAT6 pathway in patients with allergic asthma",
    "authors": [
      "A. Antczak",
      "et al."
    ],
    "year": 2016,
    "journal": "Journal of Inflammation Research",
    "doi": "10.2147/JIR.S103998",
    "citation_key": "antczak2016",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5806727/",
    "content": "STAT6是IL-4/IL-13信号通路中的关键信号转导子和转录激活子，在哮喘发病机制中起核心作用。具体机制包括：1) 促进Th1/Th2失衡，导致Th2型免疫反应优势；2) 调控B细胞产生免疫球蛋白E，STAT6表达与血清总IgE水平呈显著正相关；3) 作为转录因子调控Th2特异性基因转录；4) 与IL-4形成正反馈循环。IL-4和IL-13通过共享受体IL-4Rα激活JAK酪氨酸激酶，导致STAT6磷酸化、二聚化，然后转运至细胞核内启动Th2型炎症反应相关基因转录。"
  },
  "willskarp2008": {
    "id": "willskarp2008_il4_il13_complex",
    "title": "Untangling the Complex Web of IL-4– and IL-13–Mediated Signaling Pathways",
    "authors": [
      "M. Wills-Karp"
    ],
    "year": 2008,
    "journal": "Journal of Immunology",
    "doi": "10.4049/jimmunol.181.1.9",
    "citation_key": "willskarp2008",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4446705/",
    "content": "研究提出了一种潜在的分子机制来解释IL-4和IL-13功能差异，涉及IL-4（而非IL-13）激活STAT6的能力差异。IL-4和IL-13虽然共享受体亚基，但在STAT6激活效率上存在差异，这可能解释了它们在过敏性疾病中不同的生物学效应。"
  },
  "oh2010": {
    "id": "oh2010_stat6_therapeutics",
    "title": "Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma",
    "authors": [
      "C.K. Oh",
      "et al."
    ],
    "year": 2010,
    "journal": "European Respiratory Review",
    "doi": "10.1183/09059180.00004409",
    "citation_key": "oh2010",
    "url": "https://publications.ersnet.org/content/errev/19/115/46",
    "content": "IL-4、IL-13和STAT6是气道炎症发展的关键组成部分。STAT6作为IL-4和IL-13信号通路的下游转录因子，在哮喘的发病机制中发挥核心作用。靶向这一通路的治疗策略包括STAT6抑制剂开发，可能为哮喘治疗提供新的有效手段。"
  },
  "facheris2023": {
    "id": "facheris2023_stat6_ad",
    "title": "The translational revolution in atopic dermatitis",
    "authors": [
      "P. Facheris",
      "et al."
    ],
    "year": 2023,
    "journal": "Cellular & Molecular Immunology",
    "doi": "10.1038/s41423-023-00992-4",
    "citation_key": "facheris2023",
    "content": "STAT6是IL-4和IL-13信号通路下游的关键转录因子。在特应性皮炎中，IL-13和IL-4激活STAT6，干扰转录因子OVOL1的核转位，抑制OVOL1介导的皮肤屏障蛋白表达。STAT6的激活直接下调角质形成细胞中关键皮肤屏障蛋白的表达，包括丝聚蛋白、内披蛋白和兜甲蛋白，导致皮肤屏障功能障碍、经皮水分流失增加，形成恶性循环。STAT6还促进Th2细胞分化和IgE类别转换，其基因变异与过敏性疾病易感性相关。"
  },
  "napolitano2023": {
    "id": "napolitano2023_il13_ad",
    "title": "An overview on the role of interleukin-13 in atopic dermatitis",
    "authors": [
      "M. Napolitano",
      "et al."
    ],
    "year": 2023,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2023.1162745",
    "citation_key": "napolitano2023",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10151557/",
    "content": "IL-13在特应性皮炎中作为警报素，诱导Th2细胞和ILC2细胞产生IL-4、IL-13和IL-5。这些细胞因子通过STAT6信号通路驱动皮肤炎症反应，影响表皮屏障功能。IL-13与IL-4协同作用，通过JAK-STAT通路激活STAT6，调控皮肤炎症和屏障功能相关基因的表达。"
  },
  "kim2016": {
    "id": "kim2016_cutaneous_inflammation",
    "title": "Molecular Mechanisms of Cutaneous Inflammatory Disorder",
    "authors": [
      "J.E. Kim",
      "et al."
    ],
    "year": 2016,
    "journal": "International Journal of Molecular Sciences",
    "doi": "10.3390/ijms17081356",
    "citation_key": "kim2016",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5000632/",
    "content": "Th2细胞因子IL-4和IL-13通过抑制抗菌肽产生和减少角质形成细胞分化，对微生物入侵和表皮屏障破坏具有允许作用。这些细胞因子通过STAT6信号通路影响皮肤屏障功能，在特应性皮炎的发病机制中发挥重要作用。"
  },
  "shankar2022": {
    "id": "shankar2022_il4_il13_modulation",
    "title": "Modulation of IL-4/IL-13 cytokine signaling in the context of allergic inflammation",
    "authors": [
      "A. Shankar",
      "et al."
    ],
    "year": 2022,
    "journal": "Journal of Allergy and Clinical Immunology",
    "doi": "10.1016/j.jaci.2022.04.034",
    "citation_key": "shankar2022",
    "url": "https://www.jacionline.org/article/S0091-6749(22)00842-9/fulltext",
    "content": "越来越清楚的是，IL-4/IL-13激活的JAK/STAT通路本身可以在其他细胞内信号程序存在的情况下被调节。STAT6作为IL-4/IL-13信号通路的关键组分，其活性受到多种细胞内信号通路的交叉调控，这为理解过敏性疾病中STAT6功能的复杂性提供了新的视角。"
  },
  "junta2018": {
    "id": "junta2018_il4_il13_tuning",
    "title": "Tuning the Cytokine Responses: An Update on Interleukin-4 and Interleukin-13 Receptor Complexes",
    "authors": [
      "I.S. Junttila"
    ],
    "year": 2018,
    "journal": "Frontiers in Immunology",
    "doi": "10.3389/fimmu.2018.00888",
    "citation_key": "junta2018",
    "url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00888/full",
    "content": "IL-4和IL-13是调节过敏炎症许多方面的相关细胞因子。它们在调节淋巴细胞、髓样细胞和非造血细胞反应中发挥重要作用。这两种细胞因子通过共享受体亚基激活相似的信号通路，包括STAT6通路，但它们在受体结合亲和力和信号转导效率上存在差异，这可能解释了它们在过敏性疾病中的不同生物学功能。"
  },
  "li2022": {
    "id": "li2022_stat6_inhibitor",
    "title": "The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway",
    "authors": [
      "X. Li",
      "et al."
    ],
    "year": 2022,
    "journal": "Journal of Translational Medicine",
    "doi": "10.1186/s12967-022-03262-5",
    "citation_key": "li2022",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8851827/",
    "content": "STAT6抑制剂AS1517499是一种新型低分子量化合物，通过特异性抑制STAT6活性发挥作用。作用机制包括：1) 抑制IL-4和IL-13激活的STAT6磷酸化；2) 调节Th2/Treg细胞平衡，降低GATA3表达，增加Foxp3表达和IL-10水平；3) 降低血清IL-33水平。在特应性皮炎小鼠模型中，AS1517499显著改善皮肤病变，减轻气道炎症，改善气道高反应性，抑制气道重塑，有效阻断特应性皮炎发展为哮喘的进程。"
  },
  "kim2022": {
    "id": "kim2022_il4_il13_model",
    "title": "An Interleukin-4 and Interleukin-13 Induced Atopic Dermatitis Model",
    "authors": [
      "K. Kim",
      "et al."
    ],
    "year": 2022,
    "journal": "International Journal of Molecular Sciences",
    "doi": "10.3390/ijms23042116",
    "citation_key": "kim2022",
    "url": "https://www.mdpi.com/1422-0067/23/4/2116",
    "content": "Th2细胞因子IL-4/IL-13使用JAK启动信号传导，激活STAT6和STAT3，强烈抑制表皮分化复合物分子表达。这种抑制作用直接导致皮肤屏障功能受损，是特应性皮炎发病机制中的重要环节。IL-4和IL-13通过STAT6通路干扰角质形成细胞正常分化过程。"
  },
  "cevikbas2023": {
    "id": "cevikbas2023_eblasakimab",
    "title": "Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody for atopic dermatitis",
    "authors": [
      "F. Cevikbas",
      "et al."
    ],
    "year": 2023,
    "journal": "Journal of the American Academy of Dermatology",
    "doi": "10.1016/j.jaad.2023.04.040",
    "citation_key": "cevikbas2023",
    "url": "https://www.sciencedirect.com/science/article/pii/S1521661623004400",
    "content": "IL-4和IL-13是在Th2驱动的炎症性疾病如特应性皮炎、过敏性鼻炎和哮喘中发挥关键作用的细胞因子。这些细胞因子通过STAT6信号通路驱动疾病病理过程。靶向IL-13受体的单克隆抗体通过阻断IL-13信号传导，间接影响STAT6激活，为特应性皮炎治疗提供了新的策略。"
  }
}